BLOOD CANCER UNITED INC: Form 990, tax year 2013

View the entire original 990 at ProPublica ↗

Organization
BLOOD CANCER UNITED INC (EIN 13-5644916)
Tax period
2013-07-01 to 2014-06-30
Filed
2015-02-07
IRS object ID
201520389349300502
Schema version
2013v4.0
Source
Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header ReturnHeader

FieldValueIRS element (for citing)
Return2015-02-07T08:41:10-06:00ReturnTs
Tax Period End2014-06-30TaxPeriodEndDt

Preparer Firm PreparerFirmGrp

FieldValueIRS element (for citing)
Preparer Firm EIN135565207PreparerFirmEIN

Preparer Firm Name PreparerFirmName

FieldValueIRS element (for citing)
Business Name Line1KPMG LLPBusinessNameLine1

Preparer US Address PreparerUSAddress

FieldValueIRS element (for citing)
Address Line1345 PARK AVENUEAddressLine1
CityNEW YORKCity
StateNYState
ZIP Code101540102ZIPCode
FieldValueIRS element (for citing)
Return Type990ReturnTypeCd
Tax Period Begin2013-07-01TaxPeriodBeginDt

Filer Filer

FieldValueIRS element (for citing)
EIN135644916EIN

Business Name BusinessName

FieldValueIRS element (for citing)
Business Name Line1THE LEUKEMIA & LYMPHOMA SOCIETYINCBusinessNameLine1
Business Name Line2INCBusinessNameLine2
FieldValueIRS element (for citing)
Business Name ControlLEUKBusinessNameControlTxt
Phone9149495213PhoneNum

US Address USAddress

FieldValueIRS element (for citing)
Address Line11311 MAMARONECK AVENUEAddressLine1
Address Line2ROOM/SUITE 310AddressLine2
CityWHITE PLAINSCity
StateNYState
ZIP Code10605ZIPCode

Business Officer BusinessOfficerGrp

FieldValueIRS element (for citing)
PersonROSEMARIE LOFFREDOPersonNm
Person TitleCAO & CFOPersonTitleTxt
Phone9149495213PhoneNum
Signature2015-02-06SignatureDt
Discuss With Paid PreparerYes (true)DiscussWithPaidPreparerInd

Preparer Person PreparerPersonGrp

FieldValueIRS element (for citing)
Preparer PersonKPMG LLPPreparerPersonNm
PTINP01249521PTIN
Phone2127589700PhoneNum
Preparation2015-02-07PreparationDt
FieldValueIRS element (for citing)
Tax2013TaxYr
Build TS2016-02-25 16:41:14ZBuildTS

Form 990 IRS990

FieldValueIRS element (for citing)
Principal OfficerLOUIS J DEGENNARO PRESIDENT CEOPrincipalOfficerNm

US Address USAddress

FieldValueIRS element (for citing)
Address Line11311 MAMARONECK AVENUEAddressLine1
CityWHITE PLAINSCity
StateNYState
ZIP Code10605ZIPCode
FieldValueIRS element (for citing)
Gross Receipts$422,686,143GrossReceiptsAmt
Group Return For AffiliatesfalseGroupReturnForAffiliatesInd
Organization501c3Yes (X)Organization501c3Ind
Website AddressWWW.LLS.ORGWebsiteAddressTxt
Type Of Organization CorpYes (X)TypeOfOrganizationCorpInd
Formation1949FormationYr
Legal Domicile StateNYLegalDomicileStateCd
Activity Or MissionOUR MISSION IS TO CURE LEUKEMIA, LYMPHOMA, HODGKIN'S DISEASE AND MYELOMA, AND IMPROVE THE QUALITY OF LIFE OF PATIENTS AND THEIR FAMILIES.ActivityOrMissionDesc
Voting Members Governing Body28VotingMembersGoverningBodyCnt
Voting Members Independent28VotingMembersIndependentCnt
Total Employee1439TotalEmployeeCnt
Total Volunteers3000000TotalVolunteersCnt
Total Gross UBI$0TotalGrossUBIAmt
PY Contributions Grants$279,789,665PYContributionsGrantsAmt
CY Contributions Grants$302,437,152CYContributionsGrantsAmt
CY Program Service Revenue$0CYProgramServiceRevenueAmt
PY Investment Income$8,133,222PYInvestmentIncomeAmt
CY Investment Income$6,995,117CYInvestmentIncomeAmt
PY Other Revenue$2,435,580PYOtherRevenueAmt
CY Other Revenue$663,718CYOtherRevenueAmt
PY Total Revenue$290,358,467PYTotalRevenueAmt
CY Total Revenue$310,095,987CYTotalRevenueAmt
PY Grants And Similar Paid$117,726,007PYGrantsAndSimilarPaidAmt
CY Grants And Similar Paid$130,249,475CYGrantsAndSimilarPaidAmt
CY Benefits Paid To Members$0CYBenefitsPaidToMembersAmt
PY Salaries Comp Emp Bnft Paid$90,034,581PYSalariesCompEmpBnftPaidAmt
CY Salaries Comp Emp Bnft Paid$94,185,722CYSalariesCompEmpBnftPaidAmt
PY Total Prof Fndrsng Expns$10,134,488PYTotalProfFndrsngExpnsAmt
CY Total Prof Fndrsng Expns$7,178,370CYTotalProfFndrsngExpnsAmt
CY Total Fundraising Expense$50,314,811CYTotalFundraisingExpenseAmt
PY Other Expenses$89,083,589PYOtherExpensesAmt
CY Other Expenses$85,584,715CYOtherExpensesAmt
PY Total Expenses$306,978,665PYTotalExpensesAmt
CY Total Expenses$317,198,282CYTotalExpensesAmt
PY Revenues Less Expenses-$16,620,198PYRevenuesLessExpensesAmt
CY Revenues Less Expenses-$7,102,295CYRevenuesLessExpensesAmt
Total Assets BOY$236,325,556TotalAssetsBOYAmt
Total Assets EOY$242,581,527TotalAssetsEOYAmt
Total Liabilities BOY$135,316,123TotalLiabilitiesBOYAmt
Total Liabilities EOY$145,444,419TotalLiabilitiesEOYAmt
Net Assets Or Fund Balances BOY$101,009,433NetAssetsOrFundBalancesBOYAmt
Net Assets Or Fund Balances EOY$97,137,108NetAssetsOrFundBalancesEOYAmt
Info In Schedule O Part IIIYes (X)InfoInScheduleOPartIIIInd
MissionOUR MISSION IS TO CURE LEUKEMIA, LYMPHOMA, HODGKIN'S DISEASE AND MYELOMA, AND IMPROVE THE QUALITY OF LIFE OF PATIENTS AND THEIR FAMILIES.MissionDesc
Significant New Program SrvcfalseSignificantNewProgramSrvcInd
Significant ChangefalseSignificantChangeInd
Expense$82,095,311ExpenseAmt
Grant$78,325,341GrantAmt
DescA) RESEARCH PROGRAMS: WITH ADVISORY INPUT FROM RECOGNIZED BIOMEDICAL RESEARCH EXPERTS, LLS FUNDS EXEMPLARY PROJECTS ACROSS THE ENTIRE RESEARCH CONTINUUM RELEVANT TO IMPROVED OUTCOMES FOR BLOOD CANCER PATIENTS, FROM BASIC LABORATORY SCIENCE THROUGH CLINICAL TRIALS, AND FROM INVESTIGATOR-INITIATED RESEARCH TO PRIVATE-SECTOR DRUG DEVELOPMENT ALLIANCES. LLS IS DELIBERATE AND PURPOSEFUL IN FINDING AND SUPPORTING RESEARCH THAT IS MOST LIKELY TO HELP PATIENTS AS SOON AS POSSIBLE. (CONTINUED ON SCHEDULE O) TO DATE, LLS HAS INVESTED ALMOST 1 BILLION IN RESEARCH AIMED AT HELPING ALL BLOOD CANCER PATIENTS LIVE BETTER, LONGER LIVES. WE WILL CONTINUE TO SUPPORT RESEARCH THROUGH OUR INNOVATIVE AND INTEGRATED FUNDING PROGRAMS, UNTIL EVERY PATIENT HAS A SAFE AND EFFECTIVE THERAPY. IN FISCAL YEAR 2014, LLS SUPPORTED RESEARCH IN THE U.S., CANADA AND 7 OTHER COUNTRIES WITH A TOTAL RESEARCH DISBURSEMENT OF APPROXIMATELY 78 MILLION. RESEARCH FUNDING WAS DISTRIBUTED ACROSS ALL BLOOD CANCERS. OUR CRITICAL ROLE LLS PROGRAMS ACCELERATE RELEVANT RESEARCH OUTCOMES BY: - BUILDING A FOCUSED RESEARCH WORK-FORCE: ASSURING THE NEXT ROUND OF BREAKTHROUGHS REQUIRES THAT YOUNG INVESTIGATORS BE ENCOURAGED TO WORK IN BLOOD CANCER RESEARCH FIELDS. - TURNING DISCOVERIES INTO NEW THERAPIES: FUNDAMENTAL NEW FINDINGS CAN BE TRANSLATED INTO SAFE AND EFFECTIVE TREATMENTS THAT CAN ULTIMATELY PROLONG AND ENHANCE PATIENT LIVES. - SUPPORTING SYNERGY: LARGE GRANTS AND CONTRACTS ENABLE SCIENTISTS IN ACADEMIA AND THE PRIVATE-SECTOR TO COLLABORATE, COMBINING RESOURCES AND EXPERTISE TO PRODUCE MORE AND FASTER ADVANCES. - FILLING A VOID: RESEARCH PROJECTS THAT ARE HIGH-RISK AND/OR ADDRESS RARE CANCERS ARE LESS LIKELY TO BE FUNDED BY GOVERNMENT AGENCIES OR FOR-PROFIT COMPANIES, BUT MAY PROVIDE IMPORTANT ADVANCES. - SPEEDING NEW TREATMENTS TO PATIENTS: PARTNERING WITH BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES CAN ADVANCE PROMISING THERAPIES THROUGH CLINICAL TESTING, FASTER. PAST ADVANCES MADE WITH LLS RESEARCH FUNDING GENEROUS DONORS HAVE HELPED LLS SUPPORT RESEARCH THAT HAS ALREADY BENEFITED BLOOD CANCER PATIENTS AND MANY OTHERS. ADVANCES INCLUDE: - MULTI-DRUG THERAPIES THAT ARE MORE EFFECTIVE THAN TREATMENTS WITH SINGLE ANTI-CANCER AGENTS, - BONE MARROW / STEM CELL TRANSPLANTATION AND SUPPORTIVE CARE TREATMENTS FOR PATIENTS WHO RELAPSE DESPITE THE BEST AVAILABLE THERAPY, - TESTS THAT DISTINGUISH SPECIFIC CHARACTERISTICS OF PARTICULAR BLOOD CANCERS FOR ACCURATE DIAGNOSIS OF CANCER SUBTYPES, AND FOR "RISK STRATIFICATION" TO SELECT AN OPTIMAL THERAPY. TARGETED THERAPY RESEARCH DISCOVERING THE MOLECULAR ABNORMALITIES THAT CAUSE PARTICULAR TYPES OF BLOOD CANCER HAS BEEN USEFUL IN DIAGNOSIS AND RISK STRATIFICATION, AND IN NEW "TARGETED DRUG" DEVELOPMENT. LLS-FUNDED INVESTIGATORS HAVE HELPED ADVANCE MOLECULARLY TARGETED TREATMENTS THAT CAN SELECTIVELY KILL BLOOD CANCER CELLS VERSUS NORMAL CELLS. MANY OF THESE NEW TREATMENTS BENEFIT NOT ONLY BLOOD CANCER PATIENTS, BUT ALSO PATIENTS WITH OTHER DISEASES. FOR EXAMPLE: - GLEEVEC IS FDA-APPROVED FOR PATIENTS OF ALL AGES WITH CHRONIC MYELOID LEUKEMIA (CML), AND IS ALSO APPROVED FOR PATIENTS WITH ONE FORM OF ACUTE LYMPHOID LEUKEMIA (ALL), MYELODYSPLASTIC SYNDROMES (MDS), MYELOPROLIFERATIVE DISORDERS AND RARE FORMS OF STOMACH AND SKIN CANCERS. RELATED DRUGS, SPRYCEL AND TASIGNA, ARE APPROVED FOR PATIENTS WHO DO NOT BENEFIT FROM GLEEVEC. ONE OR MORE OF THESE DRUGS ARE ALSO SHOWING PROMISE FOR PATIENTS WITH VARIOUS LYMPHOMAS, ACUTE MYELOID LEUKEMIA (AML), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND OTHER CANCERS, INCLUDING BRAIN, BREAST, HEAD-AND-NECK, LUNG, PANCREATIC, AND PROSTATE CANCERS, AND PATIENTS WITH OTHER DISEASES INCLUDING ALZHEIMER'S, ASTHMA AND PULMONARY HYPERTENSION. - RITUXAN WAS THE FIRST FDA-APPROVED, ANTI-CANCER ANTIBODY DRUG, DEVELOPED FOR PATIENTS WITH FORMS OF B-CELL NON-HODGKIN LYMPHOMA (NHL). IT IS NOW ALSO APPROVED FOR CLL PATIENTS AND AS A "MAINTENANCE" THERAPY FOR FOLLICULAR LYMPHOMA PATIENTS, AND SHOWING PROMISE FOR PATIENTS WITH ALL AND AFTER STEM CELL TRANSPLANTATION. IN ADDITION, IT IS APPROVED FOR TREATING PATIENTS WITH SEVERE RHEUMATOID ARTHRITIS AND TWO OTHER TYPES OF AUTOIMMUNE DISEASES. A RELATED ANTIBODY DRUG, ARZERRA, IS APPROVED FOR CLL PATIENTS AND SHOWING WIDER PROMISE. - VELCADE, THALIDOMID AND REVLIMID ARE FDA-APPROVED FOR PATIENTS WITH MYELOMA AND ARE ALSO HELPING SOME PATIENTS WITH HODGKIN LYMPHOMA AND NHL. KRYPOLIS WAS RECENTLY APPROVED FOR MYELOMA PATIENTS FOR WHOM AT LEAST TWO PRIOR THERAPIES WERE INSUFFICIENT. ONE OR MORE OF THESE DRUGS ARE NOW BEING TESTED FOR PATIENTS WITH T-CELL AND B-CELL FORMS OF LYMPHOMA, ACUTE LEUKEMIAS, AS WELL AS AIDS-RELATED KAPOSI SARCOMA AND BRAIN, BREAST, COLORECTAL, HEAD-AND-NECK, KIDNEY, LIVER, LUNG, OVARIAN AND PROSTATE CANCERS, AND ALZHEIMER'S DISEASE. - ISTODAX, ZOLINZA, DACOGEN AND VIDAZA TARGET SMALL CHEMICAL, "EPIGENETIC" CHANGES. THE FIRST TWO DRUGS ARE APPROVED FOR PATIENTS WITH PERIPHERAL T-CELL LYMPHOMAS; THE LATTER DRUGS ARE APPROVED FOR MDS PATIENTS. ONE OR MORE OF THESE DRUGS ARE BEING TESTED FOR PATIENTS WITH ALL, AML, CML, CLL, MYELOMA AND FORMS OF NHL, AFTER STEM CELL TRANSPLANTATION, AND FOR PATIENTS WITH BREAST, BRAIN, KIDNEY, COLORECTAL, HEAD-AND-NECK, LUNG, STOMACH, PROSTATE AND OVARIAN CANCERS, MELANOMA AS WELL AS SICKLE CELL DISEASE AND PERSISTENT HIV INFECTIONS. - ADCETRIS WAS APPROVED IN 2011, AND IN JANUARY 2012. IT IS AN ANTIBODY- DRUG CONJUGATE THAT COMBINES AN ANTI-CD30 ANTIBODY AND THE CYTOTOXIC DRUG MONOMETHYL AURISTATIN E (MMAE). IT IS AN ANTI-NEOPLASTIC AGENT USED IN THE TREATMENT OF HODGKIN LYMPHOMA AFTER FAILURE OF AUTOLOGOUS STEM CELL TRANSPLANT OR THOSE WHO ARE NOT ELIGIBLE FOR ASCT AFTER FAILURE OF AT LEAST 2 MUTIAGEN CHEMOTHERAPY REGIMENS. ADCETRIS WAS ALSO APPROVED FOR SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA WITH FAILURE OF AT LEAST ONE PRIOR TREATMENT. - GAZYVA IS A HUMANIZED MONOCLONAL ANTIBODY USED AS A COMBINATION TREATMENT WITH CHLORAMBUCIL TO TREAT PATIENTS WITH UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA. IT WAS APPROVED BY THE FDA IN NOVEMBER 2013 AND BY THE EHA IN JULY 2014. - IMBRUVICA IS AN ORAL SMALL MOLECULE INHIBITOR AGIANST BTK KINASE. IT WAS FIRST APPROVED BY THE US FDA ON NOVEMBER 13, 2013 FOR THE TREATMENT OF MANTLE CELL LYMPHOMA PATIENTS WHO HAVE RECIEVED AT LEAST ONE PRIOR TREATMENT. ON FEB. 12, 2014 THE US FDA EXPANDED THE APPROVED USE OF THE DRUG TO CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR TREATMENT. ADDITIONALLY, IT RECEIVED FURTHER EXPANSION TO TREAT 17P DELETION IN CLL WITH OR WITHOUT PRIOR THERAPY. - ZYDELIG IS AN ORAL SMALL MOLECULE INHIBITOR THAT BLOCKS THE DELTA ISOFORM OF THE ENZYME PHOSPHOINOSITIDE 3-KINASE. IT WAS APPROVED BY THE FDA IN JULY 2014 TO TREAT RELAPSED/REFRACTORY CLL IN COMBINATION WITH RITUXAN. IT WAS ALSO APPROVED TO USE AS A MONOTHERAPY FOR RELAPSED MANTLE CELL LYMPHOMA AND FOLLICULAR LYMPHOMA. OTHER ACTIVE RESEARCH DIRECTIONS LLS-FUNDED RESEARCHERS ARE ALSO EXPLORING OTHER AREAS OF RESEARCH THAT HOLD PROMISE FOR PATIENTS: - NOVEL STEM CELL TRANSPLANTATION PROCEDURES: THESE INCLUDE SO-CALLED "MINI" TRANSPLANTS THAT USE LESS TOXIC PRE-TRANSPLANT TREATMENTS AND ENGINEERED DONOR CELLS THAT HELP REDUCE POST-TRANSPLANT COMPLICATIONS, MAKING THESE POTENTIALLY CURATIVE TREATMENTS AVAILABLE TO MORE PATIENTS. - IMMUNOTHERAPIES: INCLUDING ANTIBODIES, VACCINES AND ENGINEERED IMMUNE CELLS, THESE TARGETED THERAPIES HELP A PATIENT'S IMMUNE SYSTEM FIGHT INFECTIONS AND KILL RESIDUAL CANCER CELLS, PROLONGING REMISSIONS, AND PERHAPS ONE DAY REPLACING TOXIC CHEMOTHERAPIES. - DIAGNOSTICS: NEW TECHNOLOGIES MAKE IT POSSIBLE TO CHARACTERIZE THE ABNORMALITIES IN INDIVIDUAL CANCER CASES IN MOLECULAR DETAIL. THIS INFORMATION CAN BE USED TO HELP CHOOSE THE BEST POSSIBLE TREATMENT FOR EACH PATIENT, ESPECIALLY AS MORE TARGETED THERAPIES BECOME AVAILABLE. - QUALITY OF LIFE RESEARCH: THESE STUDIES INCREASE OUR UNDERSTANDING OF HOW SPECIFIC TREATMENTS CAN CAUSE DEBILITATING SIDE-EFFECTS, INCLUDING LATE-EFFECTS, AND WHICH PATIENTS ARE AT RISK FOR DEVELOPING THESE COMPLICATIONS, SO THAT THEY CAN BE BETTER MANAGED OR EVEN PREVENTED. DRIVING RESEARCH TO ADDRESS UNMET MEDICAL NEEDS LLS CONTINUES TO SOLICIT AND SUPPORT RESEARCH FOCUSED ON IMPROVING BLOOD CANCER PATIENTS' QUALITY OF LIFE AFTER TODAY'S CURATIVE THERAPIES. ALSO IN 2014, FOR THE THIRD YEAR, LLS ACTIVELY RECRUITED RESEARCH PROPOSALS IN SIX OTHER UNDERDEVELOPED RESEARCH AREAS IN WHICH PROGRESS IS LIKELY TO IMPROVE OUTCOMES FOR PATIENTS WITH PARTICULARLY URGENT NEEDS. NEW RESEARCH IS FOCUSED ON: - DEVELOPMENT OF NOVEL THERAPEUTIC STRATEGIES FOR PATIENTS WITH NON- CUTANEOUS T-CELL LYMPHOPROLIFERATIVE DISORDERS - DEVELOP NOVEL TARGETED THERAPIES FOR CLL PATIENTS, WITH REAL CURATIVE POTENTIAL - DEVELOP NOVEL TREATMENT STRATEGEIES FOR MDS AND AML PATIENTS - DEVELOP NOVEL TARGETED THERAPIES FOR PATIENTS WITH HIGH-RISK MYELOMA - DEVELOPMENT OF NEW-TARGETED THERAPIES FOR INDOLENT LYMPHOMA PATIENTS - DEFINE GENETIC/MOLECULAR PREDISPOSITIONSDesc

Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp

FieldValueIRS element (for citing)
Expense$96,728,148ExpenseAmt
Grant$51,924,134GrantAmt
DescB) PATIENT & COMMUNITY SERVICES: AN ESTIMATED 1,129,813 PEOPLE ACROSS THE UNITED STATES (US) CURRENTLY BATTLE LEUKEMIA, LYMPHOMA AND MYELOMA. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) OFFERS A FREE, COMPREHENSIVE ARRAY OF SERVICES TO BLOOD CANCER PATIENTS AND THEIR FAMILIES, VOLUNTEER CAREGIVERS AND ADVOCATES, HEALTHCARE PROFESSIONALS AND THE PUBLIC. (CONTINUED ON SCHEDULE O) LLS IS COMMITTED TO PROVIDING THE MOST ACCURATE AND UP-TO-DATE BLOOD CANCER INFORMATION. PROFESSIONAL VOLUNTEER CLINICAL ADVISORS WORK WITH LLS STAFF TO REVIEW ALL OF THE INFORMATION LLS PROVIDES THROUGH HEALTHCARE PROFESSIONAL AND PATIENT EDUCATION PROGRAMS, PUBLICATIONS AND THE LLS WEBSITE. A NUMBER OF RESOURCES ARE AVAILABLE IN SPANISH FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. LLS PUBLISHES AN ANNUAL COMPILATION OF DATA AVAILABLE FOR BLOOD CANCERS, INCLUDING THE ESTIMATED NUMBERS OF NEW BLOOD CANCER CASES AND DEATHS, THE MOST RECENT STATISTICS AVAILABLE FOR INCIDENCE, MORTALITY AND SURVIVAL; AND CURRENT AND ACCURATE INFORMATION ABOUT SYMPTOMS, RISK FACTORS AND TREATMENT. PUBLICATIONS AN EXTENSIVE CATALOG OF EDUCATION MATERIALS IS OFFERED FREE-OF-CHARGE TO PATIENTS AND HEALTHCARE PROFESSIONALS. EACH YEAR, LLS DISTRIBUTES BOOKLETS, BROCHURES, FACT SHEETS, EDUCATION PROGRAM TRANSCRIPTS AND DVDS THROUGH THE INFORMATION RESOURCE CENTER AND LLS CHAPTERS. MANY MATERIALS ARE ALSO AVAILABLE TO VIEW AND DOWNLOAD AT WWW.LLS.ORG/RESOURCECENTER. DOWNLOADABLE MATERIALS ARE AVAILABLE IN ENGLISH, SPANISH AND FRENCH. - 742,148 PRINTED BOOKLETS, BROCHURES, FACT SHEETS, EDUCATION PROGRAM TRANSCRIPTS AND DVDS DISTRIBUTED IN 2014. FINANCIAL ASSISTANCE IN 2014, A COMBINED 51,924,134 WAS DISBURSED TO PATIENTS THROUGH THE LLS PATIENT FINANCIAL AID (2,523,615),CO-PAY ASSISTANCE PROGRAMS (49,246,019) AND THE LLS PATIENT TRAVEL ASSISTANCE PROGRAM (154,500). PATIENT FINANCIAL ASSISTANCE PROGRAMS FOR MORE THAN 47 YEARS, LLS HAS HELPED PATIENTS DEMONSTRATING SIGNIFICANT NEED TO OBTAIN FINANCIAL ASSISTANCE TO COVER A PORTION OF THEIR TREATMENT COSTS. THE LLS PATIENT FINANCIAL ASSISTANCE PROGRAM PROVIDES A LIMITED AMOUNT OF FINANCIAL ASSISTANCE TO HELP PATIENTS WITH SIGNIFICANT FINANCIAL NEED AND WHO ARE UNDER A DOCTOR'S CARE FOR A CONFIRMED BLOOD CANCER DIAGNOSIS. PATIENT FINANCIAL ASSISTANCE FUNDS ARE SUBJECT TO AVAILABILITY. - 25,854 PATIENTS RECEIVED PATIENT FINANCIAL ASSISTANCE IN 2014. CO-PAY ASSISTANCE PROGRAM THIS CO-PAY ASSISTANCE PROGRAM HELPS PATIENTS WITH MANY KINDS OF BLOOD CANCERS MEET THEIR HEALTH INSURANCE OR MEDICARE PLAN PART B OR D PREMIUMS OR CO-PAYMENT OBLIGATIONS RELATED TO TREATING THEIR CANCER. PATIENTS WITH PRESCRIPTION DRUG COVERAGE, MEDICARE BENEFICIARIES UNDER MEDICARE PART B AND/OR MEDICARE PART D, MEDICARE SUPPLEMENTARY HEALTH INSURANCE OR MEDICARE ADVANTAGE SHOULD CHECK WITH LLS TO SEE IF THEY MEET ELIGIBILITY REQUIREMENTS TO RECEIVE FINANCIAL SUPPORT. CO-PAY ASSISTANCE IS SUBJECT TO FUND AVAILABILITY BY SPECIFIC BLOOD CANCER DIAGNOSIS. FOR MORE INFORMATION CALL, (877) LLS-COPAY (877) 557-2672 OR VISIT WWW.LLS.ORG/COPAY. - 18,640 PATIENTS RECEIVED LLS CO-PAY ASSISTANCE IN 2014 COMMUNITY PROGRAMS EACH LLS CHAPTER OFFICE IS STAFFED WITH A PATIENT SERVICES MANAGER (PSM) WHO OVERSEES SERVICES TO PATIENTS AND THEIR FAMILIES, CAREGIVERS AND HEALTHCARE PROFESSIONALS. PSMS ARE HEALTHCARE PROFESSIONALS, OFTEN WITH A BACKGROUND IN ONCOLOGY NURSING OR SOCIAL WORK. PSMS SERVE AS LIAISONS WITH COMMUNITY AND REGIONAL ONCOLOGY/HEMATOLOGY HEALTHCARE PROFESSIONALS AND TREATMENT CENTERS.COMMUNITY-BASED EDUCATION AND OUTREACH, SUPPORT AND PUBLIC POLICY AND ADVOCACY PROGRAMS ARE AVAILABLE. - 27,459 PATIENT AND CAREGIVER PARTICIPANTS ACROSS THE US IN 2014 - 10,798 HEALTHCARE PROFESSIONAL PARTICIPANTS ACROSS THE US IN 2014 PROGRAMS FOR CHILDREN AND YOUNG ADULTS THE TRISH GREENE BACK TO SCHOOL PROGRAM FOR CHILDREN WITH CANCER FOCUSES ON INCREASING COMMUNICATION AMONG HEALTHCARE PROFESSIONALS, PARENTS, PATIENTS AND SCHOOL PERSONNEL TO SUPPORT CHILDREN, ADOLESCENTS AND YOUNG ADULTS LIVING WITH CANCER. PRINTED LITERATURE, VIDEOS AND OTHER MATERIALS TO AID THE PROCESS ARE AVAILABLE IN COMMUNITIES THROUGHOUT THE US AND CANADA VIA LLS CHAPTER OFFICES. THE PROGRAM INCLUDES STAYING CONNECTED: FACILITATING THE LEARNING EXPERIENCE DURING AND AFTER CANCER TREATMENT. THIS EDUCATION PROGRAM FOR SCHOOL PERSONNEL, HEALTHCARE PROFESSIONALS AND PARENTS DESCRIBES PHYSICAL, COGNITIVE AND PSYCHOSOCIAL SHORT-AND LONG-TERM EFFECTS THAT CHILDREN, ADOLESCENTS AND YOUNG ADULTS MAY EXPERIENCE DURING AND AFTER TREATMENT. THE PROGRAM OFFERS GUIDANCE AND NUMEROUS RESOURCES TO HELP CHILDREN, ADOLESCENTS AND YOUNG ADULTS CONTINUE THEIR EDUCATION DURING AND AFTER TREATMENT. - 1,075 SCHOOL PERSONNEL, HEALTHCARE PROFESSIONALS AND PARENTS PARTICIPATED IN THE 22 STAYING CONNECTED PROGRAMS ACROSS THE US AND CANADA IN 2014. FAMILY SUPPORT GROUPS LLS HAS DEVELOPED 344 FAMILY SUPPORT GROUPS AT CHAPTERS THROUGHOUT THE US AND CANADA. LLS ALSO HAS 618 VOLUNTEER SUPPORT GROUP FACILITATORS WITH BACKGROUNDS IN ONCOLOGY NURSING OR SOCIAL WORK. GROUPS ARE GUIDED BY TWO VOLUNTEER ONCOLOGY HEALTH PROFESSIONALS, PROVIDING INFORMATION AND SUPPORT AND ENCOURAGING GREATER COMMUNICATION AMONG PATIENTS, FAMILIES, FRIENDS AND HEALTHCARE PROFESSIONALS. - 13,811 PARTICIPANTS IN FAMILY SUPPORT GROUPS ACROSS THE US IN 2014 PATTI ROBINSON KAUFMANN FIRST CONNECTION PROGRAM FIRST CONNECTION IS A PROGRAM THAT LINKS NEWLY DIAGNOSED PATIENTS TO A PEER VOLUNTEER WHO HAS EXPERIENCED A SIMILAR DIAGNOSIS. A TRAINED PATIENT-VOLUNTEER CURRENTLY IN REMISSION CONTACTS THE NEW PATIENT TO SHARE INFORMATION AND SUPPORT. THIS PROGRAM IS AVAILABLE THROUGH LLS CHAPTERS. - 5,616 FIRST CONNECTIONS ACROSS THE US IN 2014.Desc

Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp

FieldValueIRS element (for citing)
Expense$42,730,205ExpenseAmt
DescC) PUBLIC HEALTH EDUCATION: INFORMATION AND EDUCATION INFORMATION RESOURCE CENTER PAYING FOR MEDICAL CARE, MAKING TREATMENT CHOICES, COMMUNICATING WITH HEALTHCARE PROVIDERS, FAMILY MEMBERS AND FRIENDS-THESE ARE SOME OF THE STRESSES THAT COME WITH A CANCER DIAGNOSIS. (CONTINUED ON SCHEDULE O) LLS INFORMATION SPECIALISTS ARE MASTER'S LEVEL ONCOLOGY SOCIAL WORKERS, NURSES AND HEALTH EDUCATORS WHO PROVIDE HELP WITH DISEASE, TREATMENT AND CLINICAL TRIAL INFORMATION AND SUPPORT. LLS INFORMATION SPECIALISTS CONDUCT CLINICAL-TRIAL SEARCHES TO HELP PATIENTS WORK WITH THEIR DOCTORS TO FIND OUT ABOUT SPECIFIC CLINICAL TRIALS. PATIENTS, FAMILIES AND HEALTHCARE PROFESSIONALS MAY SPEAK TO AN INFORMATION SPECIALIST AT (800) 955-4572 MONDAY THROUGH FRIDAY, 9 A.M. TO 9 P.M., ET, EMAIL INFOCENTER@LLS.ORG OR CHAT ONE-ON-ONE VIA THE LLS WEBSITE. THE INFORMATION RESOURCE CENTER OFFERS TRANSLATION SERVICES IN MORE THAN 165 LANGUAGES. - 48,326 INQUIRIES IN 2014 THE LLS WEBSITE THE LLS WEBSITE, WWW.LLS.ORG, FULFILLS A WIDE VARIETY OF EDUCATION AND INFORMATION NEEDS. VISITORS CAN PERSONALIZE THEIR WEB PAGES TO THEIR LOCATION TO KEEP CURRENT WITH DISEASE-SPECIFIC UPDATES AND COMMUNITY EDUCATION AND SUPPORT ACTIVITIES. THE WEBSITE PROVIDES ACCESS TO LLS PROGRAMS AND SERVICES, INCLUDING CO-PAY ASSISTANCE, THE MOST CURRENT AND ACCURATE INFORMATION AND STATISTICS, WEEKLY FACILITATED ONLINE CHATS, NATIONAL TELEPHONE AND WEB EDUCATION PROGRAMS, PUBLICATIONS IN ENGLISH, SPANISH AND FRENCH, AND CLINICAL-TRIAL SEARCHES VIA AN ONLINE CLINICAL- TRIAL SEARCH SERVICE THAT OFFERS PATIENTS AND CAREGIVERS IMMEDIATE ACCESS TO LISTINGS OF BLOOD CANCER CLINICAL TRIALS. PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS CAN INTERACT WITH LLS AND ONE ANOTHER THROUGH SOCIAL NETWORKING, PODCASTS AND ENEWSLETTERS. NATIONAL TELEPHONE/ WEB EDUCATION PROGRAMS LLS SPONSORS TELEPHONE AND WEB EDUCATION PROGRAMS FOR PATIENTS, CAREGIVERS, SURVIVORS AND HEALTHCARE PROFESSIONALS ABOUT LEUKEMIA, LYMPHOMA, MYELOMA AND MYELODYSPLASTIC SYNDROMES. IN 2014, 9 LLS NATIONAL EDUCATION PROGRAMS FEATURED DISEASE-SPECIFIC UPDATES AND INFORMATION ABOUT SUPPORT AND TREATMENT OPTIONS FROM WORLD RENOWNED CLINICAL EXPERTS. OPPORTUNITIES ARE PROVIDED TO ASK QUESTIONS OF EXPERTS DURING THESE PROGRAMS. THESE PROGRAMS OFFER CONTINUING EDUCATION CREDITS FOR NURSES AND SOCIAL WORKERS. LLS ALSO SPONSORS A RANGE OF PROFESSIONAL EDUCATION PROGRAMS. RECENT PROGRAMS EXPLORED THE ADMINISTRATION AND MANAGEMENT OF CURRENT THERAPIES FOR HEMATOLOGIC MALIGNANCIES AND COMMUNICATION AMONG PRIMARY CARE PROVIDERS AND HEMATOLOGISTS/ONCOLOGISTS IN MANAGING PATIENTS WITH HEMATOLOGIC CANCER. UPCOMING PROGRAMS ARE POSTED AT WWW.LLS.ORG/PROGRAMS AND ARCHIVES OF PAST PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/PASTPROGRAMS. PROFESSIONAL EDUCATION PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/PROFESSIONALED. LLS ALSO OFFERS DISEASE-SPECIFIC WEBCASTS PRESENTED BY WORLD RENOWNED CLINICAL EXPERTS. THESE CAN BE ACCESSED AT WWW.LLS.ORG/WEBCASTS.Desc

Prog Srvc Accom Acty Other ProgSrvcAccomActyOtherGrp

FieldValueIRS element (for citing)
Expense$19,047,085ExpenseAmt
DescD) PROFESSIONAL EDUCATION: LLS SERVES THE EDUCATIONAL NEEDS OF THE MEDICAL AND RESEARCH COMMUNITY THROUGH A NUMBER OF PROFESSIONAL EDUCATION SYMPOSIA OFFERED THROUGHOUT THE YEAR. THE EDUCATIONAL PROGRAM OFFERS VARYING FORMATS TO FACILITATE THE EXCHANGE OF INFORMATION AND IDEAS ON THE NEWEST DEVELOPMENTS IN CANCER RESEARCH AND TREATMENT.Desc
FieldValueIRS element (for citing)
Total Other Prog Srvc Expense$19,047,085TotalOtherProgSrvcExpenseAmt
Total Program Service Expenses$240,600,749TotalProgramServiceExpensesAmt
Described In Section501c3Yes (true)DescribedInSection501c3Ind
Schedule B RequiredYes (true)ScheduleBRequiredInd
Political Campaign ActyfalsePoliticalCampaignActyInd
Lobbying ActivitiesYes (true)LobbyingActivitiesInd
Subject To Proxy TaxfalseSubjectToProxyTaxInd
Donor Advised FundfalseDonorAdvisedFundInd
Conservation EasementsfalseConservationEasementsInd
Collections Of ArtYes (true)CollectionsOfArtInd
Credit CounselingfalseCreditCounselingInd
Temp Or Permanent EndowmentsYes (true)TempOrPermanentEndowmentsInd
Report Land Building EquipmentYes (true)ReportLandBuildingEquipmentInd
Report Investments Other SecYes (true)ReportInvestmentsOtherSecInd
Report Program Related InvstfalseReportProgramRelatedInvstInd
Report Other AssetsfalseReportOtherAssetsInd
Report Other LiabilitiesfalseReportOtherLiabilitiesInd
Include FIN48 FootnoteYes (true)IncludeFIN48FootnoteInd
Independent Audit Fincl StmtfalseIndependentAuditFinclStmtInd
Consolidated Audit Fincl StmtYes (true)ConsolidatedAuditFinclStmtInd
School OperatingfalseSchoolOperatingInd
Foreign OfficeYes (true)ForeignOfficeInd
Foreign ActivitiesYes (true)ForeignActivitiesInd
More Than5000 K To OrgYes (true)MoreThan5000KToOrgInd
More Than5000 K To IndividualsfalseMoreThan5000KToIndividualsInd
Professional FundraisingYes (true)ProfessionalFundraisingInd
Fundraising ActivitiesYes (true)FundraisingActivitiesInd
Gaming ActivitiesYes (true)GamingActivitiesInd
Operate HospitalfalseOperateHospitalInd
Grants To OrganizationsYes (true)GrantsToOrganizationsInd
Grants To IndividualsYes (true)GrantsToIndividualsInd
Schedule J RequiredYes (true)ScheduleJRequiredInd
Tax Exempt BondsfalseTaxExemptBondsInd
Engaged In Excess Benefit TransfalseEngagedInExcessBenefitTransInd
PY Excess Benefit TransfalsePYExcessBenefitTransInd
Loan OutstandingfalseLoanOutstandingInd
Grant To Related PersonfalseGrantToRelatedPersonInd
Business Rln With Org MemfalseBusinessRlnWithOrgMemInd
Business Rln With Fam MemfalseBusinessRlnWithFamMemInd
Business Rln With Officer EntfalseBusinessRlnWithOfficerEntInd
Deductible Non Cash ContriYes (true)DeductibleNonCashContriInd
Deductible Art ContributionfalseDeductibleArtContributionInd
Terminate OperationsfalseTerminateOperationsInd
Partial LiquidationfalsePartialLiquidationInd
Disregarded EntityfalseDisregardedEntityInd
Related EntityYes (true)RelatedEntityInd
Related Organization Ctrl EntYes (true)RelatedOrganizationCtrlEntInd
Transaction With Control EntYes (true)TransactionWithControlEntInd
Trnsfr Exmpt Non Chrtbl Rltd OrgfalseTrnsfrExmptNonChrtblRltdOrgInd
Activities Conducted PrtshpfalseActivitiesConductedPrtshpInd
Schedule O RequiredYes (true)ScheduleORequiredInd
Info In Schedule O Part VYes (X)InfoInScheduleOPartVInd
IRP Document998IRPDocumentCnt
IRP Document W2 G24IRPDocumentW2GCnt
Backup Wthld ComplianceYes (true)BackupWthldComplianceInd
Employee1439EmployeeCnt
Employment Tax Returns FiledYes (true)EmploymentTaxReturnsFiledInd
Unrelated Bus Incm Over LimitfalseUnrelatedBusIncmOverLimitInd
Foreign Financial AccountYes (true)ForeignFinancialAccountInd
Foreign CountryCAForeignCountryCd
Prohibited Tax Shelter TransfalseProhibitedTaxShelterTransInd
Taxable Party NotificationfalseTaxablePartyNotificationInd
Nondeductible ContributionsfalseNondeductibleContributionsInd
Quid Pro Quo ContributionsYes (true)QuidProQuoContributionsInd
Quid Pro Quo Contri DisclYes (true)QuidProQuoContriDisclInd
Form8282 Property Disposed OffalseForm8282PropertyDisposedOfInd
Rcv Fnds To Pay Prsnl Bnft CntrctfalseRcvFndsToPayPrsnlBnftCntrctInd
Pay Premiums Prsnl Bnft CntrctfalsePayPremiumsPrsnlBnftCntrctInd
Indoor Tanning ServicesfalseIndoorTanningServicesInd
Info In Schedule O Part VIYes (X)InfoInScheduleOPartVIInd
Governing Body Voting Members28GoverningBodyVotingMembersCnt
Independent Voting Member28IndependentVotingMemberCnt
Family Or Business RlnfalseFamilyOrBusinessRlnInd
Delegation Of Mgmt DutiesfalseDelegationOfMgmtDutiesInd
Change To Org DocumentsYes (true)ChangeToOrgDocumentsInd
Material Diversion Or MisusefalseMaterialDiversionOrMisuseInd
Members Or StockholdersYes (true)MembersOrStockholdersInd
Election Of Board MembersYes (true)ElectionOfBoardMembersInd
Decisions Subject To ApprovaYes (true)DecisionsSubjectToApprovaInd
Minutes Of Governing BodyYes (true)MinutesOfGoverningBodyInd
Minutes Of CommitteesYes (true)MinutesOfCommitteesInd
Officer Mailing AddressfalseOfficerMailingAddressInd
Local ChaptersYes (true)LocalChaptersInd
Policies Reference ChaptersYes (true)PoliciesReferenceChaptersInd
Form990 Provided To Gvrn BodyYes (true)Form990ProvidedToGvrnBodyInd
Conflict Of Interest PolicyYes (true)ConflictOfInterestPolicyInd
Annual Disclosure Covered PrsnYes (true)AnnualDisclosureCoveredPrsnInd
Regular Monitoring EnfrcYes (true)RegularMonitoringEnfrcInd
Whistleblower PolicyYes (true)WhistleblowerPolicyInd
Document Retention PolicyYes (true)DocumentRetentionPolicyInd
Compensation Process CEOYes (true)CompensationProcessCEOInd
Compensation Process OtherYes (true)CompensationProcessOtherInd
Investment In Joint VenturefalseInvestmentInJointVentureInd
States Where Copy Of Return Is FldAKStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldALStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldARStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldAZStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldCAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldCOStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldCTStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldDEStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldDCStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldFLStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldGAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldHIStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldIDStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldILStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldINStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldKSStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldKYStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldLAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMDStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMEStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMIStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMNStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMOStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMSStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNHStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNJStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNMStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNEStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNYStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldOHStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldOKStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldORStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldPAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldPRStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldRIStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldSCStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldTNStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldUTStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldVAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldWAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldWIStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldWVStatesWhereCopyOfReturnIsFldCd
Own WebsiteYes (X)OwnWebsiteInd
Upon RequestYes (X)UponRequestInd

Books In Care Of Detail BooksInCareOfDetail

FieldValueIRS element (for citing)
PersonROSEMARIE LOFFREDOPersonNm
Phone9149495213PhoneNum

US Address USAddress

FieldValueIRS element (for citing)
Address Line11311 MAMARONECK AVENUEAddressLine1
CityWHITE PLAINSCity
StateNYState
ZIP Code10605ZIPCode

Form990 Part VII Section A Form990PartVIISectionAGrp (37 entries)

TitleTitleTxtAverage Hours Per WeekAverageHoursPerWeekRtIndividual Trustee Or DirectorIndividualTrusteeOrDirectorIndReportable Comp From OrgReportableCompFromOrgAmtReportable Comp From Rltd OrgReportableCompFromRltdOrgAmtOther CompensationOtherCompensationAmtAverage Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRtOfficerOfficerIndHighest Compensated EmployeeHighestCompensatedEmployeeInd
JAMES A BECK
BOD MEMBER2.00Yes (X)$0$0$0
WILLIAM G BEHNKE
BOD MEMBER2.00Yes (X)$0$0$0
JORGE L BENITEZ
BOD MEMBER2.00Yes (X)$0$0$0
PETER B BROCK
BOD MEMBER2.00Yes (X)$0$0$0
A DANA CALLOW JR
BOD MEMBER2.00Yes (X)$0$0$0
SCOTT A CARROLL
BOD MEMBER2.00Yes (X)$0$0$0
ELIZABETH J CLARK
BOD MEMBER2.00Yes (X)$0$0$0
RODMAN N MYERS
LIFE MEMBER2.00Yes (X)$0$0$0
JAMES H DAVIS PHD
VICE CHAIR2.00Yes (X)$0$0$03.00Yes (X)
TIMOTHY DURST
CHAIR2.00Yes (X)$0$0$03.00Yes (X)
BERNARD H GARIL
BOD MEMBER2.00Yes (X)$0$0$0
PAMELA JO HAYLOCK
BOD MEMBER2.00Yes (X)$0$0$0
RAANAN HOROWITZ
BOD MEMBER2.00Yes (X)$0$0$0
RICHARD M JEANNERET
BOD MEMBER2.00Yes (X)$0$0$0
RALPH LAWSON
BOD MEMBER2.00Yes (X)$0$0$0
JOSEPH B KELLEY
BOD MEMBER2.00Yes (X)$0$0$0
MARIE V MCDEMMOND
BOD MEMBER2.00Yes (X)$0$0$0
STEVEN T ROSENMDFACP
BOD MEMBER2.00Yes (X)$0$0$0
KENNETH M SCHWARTZ
SECRETARY/TR2.00Yes (X)$0$0$03.00Yes (X)
KATHRYN C VECELLIO
BOD MEMBER2.00Yes (X)$0$0$0
LOUISE E WARNER
BOD MEMBER2.00Yes (X)$0$0$0
JAMES E BRADNER
BOD MEMBER2.00Yes (X)$0$0$0
BETH E HAWLEY
BOD MEMBER2.00Yes (X)$0$0$0
GILLES LEGAULT
BOD MEMBER2.00Yes (X)$0$0$0
DONALD PROCTOR
BOD MEMBER2.00Yes (X)$0$0$0
FRANK O SMITH
BOD MEMBER2.00Yes (X)$0$0$0
KEITH S WHITE
BOD MEMBER2.00Yes (X)$0$0$0
GRACIELA C ELETA
BOD MEMBER2.00Yes (X)$0$0$0
JOHN E WALTER
PRES&CEO TER45.00$628,359$0$63,3463.00Yes (X)
LOUIS J DEGENNARO
PRESIDENT &45.00$446,200$0$94,3073.00Yes (X)
JAMES T NANGLE
SVP&CFO TERM45.00$408,402$0$42,373Yes (X)
ROSEMARIE A LOFFREDO
CAO&CFO STAR45.00$136,466$0$5,319Yes (X)
LISA STOCKMON
EVP-CHIEF MK45.00$348,455$0$35,824Yes (X)
GEORGE J OMIROS
EVP-CHIEF CA45.00$334,718$0$45,253Yes (X)
MARK VELLECA
CHIEF POLICY45.00$323,322$0$47,780Yes (X)
MARK ROITHMAYR
CHIEF DEVELO45.00$320,714$0$25,806Yes (X)
BRIAN ROSEN
CHIEF POLICY45.00$282,497$0$33,649Yes (X)
FieldValueIRS element (for citing)
Total Reportable Comp From Org$3,229,133TotalReportableCompFromOrgAmt
Total Other Compensation$393,657TotalOtherCompensationAmt
Indiv Rcvd Greater Than100 K145IndivRcvdGreaterThan100KCnt
Former Ofcr Employees ListedfalseFormerOfcrEmployeesListedInd
Total Comp Greater Than150 KYes (true)TotalCompGreaterThan150KInd
Compensation From Other SrcsfalseCompensationFromOtherSrcsInd

Contractor Compensation ContractorCompensationGrp (5 entries)

Address Line1ContractorAddress/USAddress/AddressLine1CityContractorAddress/USAddress/CityStateContractorAddress/USAddress/StateZIP CodeContractorAddress/USAddress/ZIPCodeServicesServicesDescCompensationCompensationAmt
OLIVER STAFFING INC
350 LEXINGTON AV SUITE 401NEW YORKNY10016TEMP STAFFING$6,567,519
PATIENT ADVOCACY FOUNDATION
421 BUTLER FARM RDHAMPTONVA23666PAT ASSIST PROC$4,567,715
MAIL AMERICA
174 ELKTON FARM RDFORESTVA24551FUNDRAISING SER$3,745,936
INFOCISION
325 SPRINGSIDE DRIVEAKRONOH44333FUNDRASING SERV$1,728,035
PARADYZ MATERA
5 HANOVER SQUARENEW YORKNY10004FUNDRAISING SER$1,320,036
FieldValueIRS element (for citing)
Cntrct Rcvd Greater Than100 K54CntrctRcvdGreaterThan100KCnt
Federated Campaigns$2,194,082FederatedCampaignsAmt
Fundraising$163,590,328FundraisingAmt
Related Organizations$58,002RelatedOrganizationsAmt
All Other Contributions$136,594,740AllOtherContributionsAmt
Noncash Contributions$890,755NoncashContributionsAmt
Total Contributions$302,437,152TotalContributionsAmt

Investment Income InvestmentIncomeGrp

FieldValueIRS element (for citing)
Total Revenue Column$1,200,545TotalRevenueColumnAmt
Exclusion$1,200,545ExclusionAmt

Royalties Revenue RoyaltiesRevenueGrp

FieldValueIRS element (for citing)
Total Revenue Column$3,320TotalRevenueColumnAmt
Exclusion$3,320ExclusionAmt

Gross Amount Sales Assets GrossAmountSalesAssetsGrp

FieldValueIRS element (for citing)
Securities$90,871,363SecuritiesAmt

Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp

FieldValueIRS element (for citing)
Securities$85,076,791SecuritiesAmt

Gain Or Loss GainOrLossGrp

FieldValueIRS element (for citing)
Securities$5,794,572SecuritiesAmt

Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp

FieldValueIRS element (for citing)
Total Revenue Column$5,794,572TotalRevenueColumnAmt
Exclusion$5,794,572ExclusionAmt
FieldValueIRS element (for citing)
Fundraising Gross Income$27,272,894FundraisingGrossIncomeAmt
Contri Rpt Fundraising Event$163,590,328ContriRptFundraisingEventAmt
Fundraising Direct Expenses$27,272,894FundraisingDirectExpensesAmt
Gaming Gross Income$795,990GamingGrossIncomeAmt
Gaming Direct Expenses$240,471GamingDirectExpensesAmt

Net Income From Gaming NetIncomeFromGamingGrp

FieldValueIRS element (for citing)
Total Revenue Column$555,519TotalRevenueColumnAmt
Exclusion$555,519ExclusionAmt

Other Revenue Misc OtherRevenueMiscGrp

FieldValueIRS element (for citing)
DescOTHER MISCELLANEOUSDesc
Business900099BusinessCd
Total Revenue Column$104,879TotalRevenueColumnAmt
Exclusion$104,879ExclusionAmt
FieldValueIRS element (for citing)
Other Revenue Total$104,879OtherRevenueTotalAmt

Total Revenue TotalRevenueGrp

FieldValueIRS element (for citing)
Total Revenue Column$310,095,987TotalRevenueColumnAmt
Exclusion$7,658,835ExclusionAmt

Grants To Domestic Orgs GrantsToDomesticOrgsGrp

FieldValueIRS element (for citing)
Total$69,785,159TotalAmt
Program Services$69,785,159ProgramServicesAmt

Grants To Domestic Individuals GrantsToDomesticIndividualsGrp

FieldValueIRS element (for citing)
Total$51,924,134TotalAmt
Program Services$51,924,134ProgramServicesAmt

Foreign Grants ForeignGrantsGrp

FieldValueIRS element (for citing)
Total$8,540,182TotalAmt
Program Services$8,540,182ProgramServicesAmt

Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp

FieldValueIRS element (for citing)
Total$818,776TotalAmt
Program Services$569,152ProgramServicesAmt
Management And General$110,390ManagementAndGeneralAmt
Fundraising$139,234FundraisingAmt

Other Salaries And Wages OtherSalariesAndWagesGrp

FieldValueIRS element (for citing)
Total$72,881,314TotalAmt
Program Services$50,661,660ProgramServicesAmt
Management And General$9,826,189ManagementAndGeneralAmt
Fundraising$12,393,465FundraisingAmt

Pension Plan Contributions PensionPlanContributionsGrp

FieldValueIRS element (for citing)
Total$4,359,951TotalAmt
Program Services$2,837,221ProgramServicesAmt
Management And General$714,376ManagementAndGeneralAmt
Fundraising$808,354FundraisingAmt

Other Employee Benefits OtherEmployeeBenefitsGrp

FieldValueIRS element (for citing)
Total$11,051,482TotalAmt
Program Services$7,191,706ProgramServicesAmt
Management And General$1,810,781ManagementAndGeneralAmt
Fundraising$2,048,995FundraisingAmt

Payroll Taxes PayrollTaxesGrp

FieldValueIRS element (for citing)
Total$5,074,199TotalAmt
Program Services$3,302,015ProgramServicesAmt
Management And General$831,405ManagementAndGeneralAmt
Fundraising$940,779FundraisingAmt

Fees For Services Legal FeesForServicesLegalGrp

FieldValueIRS element (for citing)
Total$704,547TotalAmt
Program Services$386,222ProgramServicesAmt
Management And General$118,487ManagementAndGeneralAmt
Fundraising$199,838FundraisingAmt

Fees For Services Accounting FeesForServicesAccountingGrp

FieldValueIRS element (for citing)
Total$276,417TotalAmt
Program Services$151,527ProgramServicesAmt
Management And General$46,486ManagementAndGeneralAmt
Fundraising$78,404FundraisingAmt

Fees For Services Lobbying FeesForServicesLobbyingGrp

FieldValueIRS element (for citing)
Total$558,530TotalAmt
Program Services$306,176ProgramServicesAmt
Management And General$93,931ManagementAndGeneralAmt
Fundraising$158,423FundraisingAmt

Fees For Services Prof Fundraising FeesForServicesProfFundraising

FieldValueIRS element (for citing)
Total$7,178,370TotalAmt
Fundraising$7,178,370FundraisingAmt

Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp

FieldValueIRS element (for citing)
Total$198,971TotalAmt
Program Services$109,074ProgramServicesAmt
Management And General$33,462ManagementAndGeneralAmt
Fundraising$56,435FundraisingAmt

Fees For Services Other FeesForServicesOtherGrp

FieldValueIRS element (for citing)
Total$17,118,168TotalAmt
Program Services$9,383,918ProgramServicesAmt
Management And General$2,878,834ManagementAndGeneralAmt
Fundraising$4,855,416FundraisingAmt

Advertising AdvertisingGrp

FieldValueIRS element (for citing)
Total$11,443,327TotalAmt
Program Services$4,600,579ProgramServicesAmt
Management And General$1,727,542ManagementAndGeneralAmt
Fundraising$5,115,206FundraisingAmt

Office Expenses OfficeExpensesGrp

FieldValueIRS element (for citing)
Total$24,283,597TotalAmt
Program Services$10,735,405ProgramServicesAmt
Management And General$3,515,242ManagementAndGeneralAmt
Fundraising$10,032,950FundraisingAmt

Information Technology InformationTechnologyGrp

FieldValueIRS element (for citing)
Total$5,796,747TotalAmt
Program Services$3,177,688ProgramServicesAmt
Management And General$974,862ManagementAndGeneralAmt
Fundraising$1,644,197FundraisingAmt

Occupancy OccupancyGrp

FieldValueIRS element (for citing)
Total$8,442,768TotalAmt
Program Services$5,677,843ProgramServicesAmt
Management And General$1,330,818ManagementAndGeneralAmt
Fundraising$1,434,107FundraisingAmt

Travel TravelGrp

FieldValueIRS element (for citing)
Total$5,174,411TotalAmt
Program Services$3,495,450ProgramServicesAmt
Management And General$683,781ManagementAndGeneralAmt
Fundraising$995,180FundraisingAmt

Conferences Meetings ConferencesMeetingsGrp

FieldValueIRS element (for citing)
Total$3,874,939TotalAmt
Program Services$2,938,562ProgramServicesAmt
Management And General$251,127ManagementAndGeneralAmt
Fundraising$685,250FundraisingAmt

Depreciation Depletion DepreciationDepletionGrp

FieldValueIRS element (for citing)
Total$3,928,364TotalAmt
Program Services$2,372,972ProgramServicesAmt
Management And General$750,378ManagementAndGeneralAmt
Fundraising$805,014FundraisingAmt

Insurance InsuranceGrp

FieldValueIRS element (for citing)
Total$600,054TotalAmt
Program Services$386,432ProgramServicesAmt
Management And General$103,072ManagementAndGeneralAmt
Fundraising$110,550FundraisingAmt

Other Expenses OtherExpensesGrp (2 entries)

DescDescTotalTotalAmtProgram ServicesProgramServicesAmtManagement And GeneralManagementAndGeneralAmtFundraisingFundraisingAmt
MISCELLANEOUS$2,887,044$1,948,337$436,748$501,959
DUES & SUBSCRIPTIONS$296,831$119,335$44,811$132,685

Total Functional Expenses TotalFunctionalExpensesGrp

FieldValueIRS element (for citing)
Total$317,198,282TotalAmt
Program Services$240,600,749ProgramServicesAmt
Management And General$26,282,722ManagementAndGeneralAmt
Fundraising$50,314,811FundraisingAmt
FieldValueIRS element (for citing)
Joint CostsYes (X)JointCostsInd

Total Joint Costs TotalJointCostsGrp

FieldValueIRS element (for citing)
Total$20,809,131TotalAmt
Program Services$8,971,856ProgramServicesAmt
Fundraising$11,837,275FundraisingAmt

Cash Non Interest Bearing CashNonInterestBearingGrp

FieldValueIRS element (for citing)
BOY$5,620,937BOYAmt
EOY$6,268,949EOYAmt

Savings And Temp Cash Invst SavingsAndTempCashInvstGrp

FieldValueIRS element (for citing)
BOY$19,656,020BOYAmt
EOY$20,220,498EOYAmt

Pledges And Grants Receivable PledgesAndGrantsReceivableGrp

FieldValueIRS element (for citing)
BOY$7,252,079BOYAmt
EOY$8,575,572EOYAmt

Accounts Receivable AccountsReceivableGrp

FieldValueIRS element (for citing)
BOY$81,719BOYAmt
EOY$311EOYAmt

Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp

FieldValueIRS element (for citing)
BOY$4,851,345BOYAmt
EOY$4,955,078EOYAmt
FieldValueIRS element (for citing)
Land Bldg Equip Cost Or Other Bss$31,199,936LandBldgEquipCostOrOtherBssAmt
Land Bldg Equip Accum Deprec$14,790,328LandBldgEquipAccumDeprecAmt

Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp

FieldValueIRS element (for citing)
BOY$10,594,159BOYAmt
EOY$16,409,608EOYAmt

Investments Pub Traded Sec InvestmentsPubTradedSecGrp

FieldValueIRS element (for citing)
BOY$112,406,398BOYAmt
EOY$125,935,503EOYAmt

Investments Other Securities InvestmentsOtherSecuritiesGrp

FieldValueIRS element (for citing)
BOY$75,862,899BOYAmt
EOY$60,216,008EOYAmt

Total Assets TotalAssetsGrp

FieldValueIRS element (for citing)
BOY$236,325,556BOYAmt
EOY$242,581,527EOYAmt

Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp

FieldValueIRS element (for citing)
BOY$20,652,928BOYAmt
EOY$20,275,231EOYAmt

Grants Payable GrantsPayableGrp

FieldValueIRS element (for citing)
BOY$80,460,957BOYAmt
EOY$99,130,986EOYAmt

Deferred Revenue DeferredRevenueGrp

FieldValueIRS element (for citing)
BOY$34,202,238BOYAmt
EOY$26,038,202EOYAmt

Total Liabilities TotalLiabilitiesGrp

FieldValueIRS element (for citing)
BOY$135,316,123BOYAmt
EOY$145,444,419EOYAmt
FieldValueIRS element (for citing)
Organization Follows SFAS117Yes (X)OrganizationFollowsSFAS117Ind

Unrestricted Net Assets UnrestrictedNetAssetsGrp

FieldValueIRS element (for citing)
BOY$90,324,737BOYAmt
EOY$67,582,758EOYAmt

Temporarily Rstr Net Assets TemporarilyRstrNetAssetsGrp

FieldValueIRS element (for citing)
BOY$7,775,266BOYAmt
EOY$26,592,408EOYAmt

Permanently Rstr Net Assets PermanentlyRstrNetAssetsGrp

FieldValueIRS element (for citing)
BOY$2,909,430BOYAmt
EOY$2,961,942EOYAmt

Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp

FieldValueIRS element (for citing)
BOY$101,009,433BOYAmt
EOY$97,137,108EOYAmt

Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp

FieldValueIRS element (for citing)
BOY$236,325,556BOYAmt
EOY$242,581,527EOYAmt
FieldValueIRS element (for citing)
Info In Schedule O Part XIYes (X)InfoInScheduleOPartXIInd
Reconcilation Revenue Expnss-$7,102,295ReconcilationRevenueExpnssAmt
Net Unrlzd Gains Losses Invst$6,349,371NetUnrlzdGainsLossesInvstAmt
Other Changes In Net Assets-$3,119,401OtherChangesInNetAssetsAmt
Info In Schedule O Part XIIYes (X)InfoInScheduleOPartXIIInd
Method Of Accounting AccrualYes (X)MethodOfAccountingAccrualInd
Accountant Compile Or ReviewYes (true)AccountantCompileOrReviewInd
FS AuditedYes (true)FSAuditedInd

FS Audited Basis FSAuditedBasisGrp

FieldValueIRS element (for citing)
Consolidated Basis Fincl StmtYes (X)ConsolidatedBasisFinclStmtInd
FieldValueIRS element (for citing)
Audit CommitteeYes (true)AuditCommitteeInd
Federal Grant Audit RequiredfalseFederalGrantAuditRequiredInd

Schedule A IRS990ScheduleA

FieldValueIRS element (for citing)
Public Organization170Yes (X)PublicOrganization170Ind

Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$238,080,823CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$270,043,865CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$282,672,072CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$279,789,664CurrentTaxYearMinus1YearAmt
Current Tax Year$302,437,152CurrentTaxYearAmt
Total$1,373,023,576TotalAmt

Total Calendar Year170 TotalCalendarYear170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$238,080,823CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$270,043,865CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$282,672,072CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$279,789,664CurrentTaxYearMinus1YearAmt
Current Tax Year$302,437,152CurrentTaxYearAmt
Total$1,373,023,576TotalAmt
FieldValueIRS element (for citing)
Substantial Contributors Tot$194,613,347SubstantialContributorsTotAmt
Public Support Total170$1,178,410,229PublicSupportTotal170Amt

Gross Investment Income170 GrossInvestmentIncome170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$4,962,639CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$3,145,637CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$2,705,046CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$2,260,636CurrentTaxYearMinus1YearAmt
Current Tax Year$1,203,865CurrentTaxYearAmt
Total$14,277,823TotalAmt

Other Income170 OtherIncome170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$1,925,834CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$1,779,485CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$1,502,044CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$1,974,227CurrentTaxYearMinus1YearAmt
Current Tax Year$104,879CurrentTaxYearAmt
Total$7,286,469TotalAmt
FieldValueIRS element (for citing)
Total Support$1,394,587,868TotalSupportAmt
Gross Receipts Rltd Activities$171,720,181GrossReceiptsRltdActivitiesAmt
Public Support CY1700.84500PublicSupportCY170Pct
Public Support PY1700.87530PublicSupportPY170Pct
Thirty Thr Pct Suprt Tests CY170Yes (X)ThirtyThrPctSuprtTestsCY170Ind

Form990 Schedule A Part IV Form990ScheduleAPartIVGrp

FieldValueIRS element (for citing)
Form And Line ReferencePART II, LINE 10FormAndLineReferenceDesc
ExplanationGRANT TERMINATIONS & REFUNDS 6,966,780 OTHER MISC. REVENUE 319,689ExplanationTxt

Schedule B IRS990ScheduleB

Contributor Information ContributorInformationGrp

FieldValueIRS element (for citing)
ContributorRESTRICTEDContributorNum

Contributor Business Name ContributorBusinessName

FieldValueIRS element (for citing)
Business Name Line1RESTRICTEDBusinessNameLine1

Contributor US Address ContributorUSAddress

FieldValueIRS element (for citing)
Address Line1RESTRICTEDAddressLine1
Address Line2RESTRICTEDAddressLine2
CityRESTRICTEDCity
StateRESTRICTEDState
ZIP CodeRESTRICTEDZIPCode
FieldValueIRS element (for citing)
Total ContributionsRESTRICTEDTotalContributionsAmt

Schedule C IRS990ScheduleC

FieldValueIRS element (for citing)
VolunteersYes (true)VolunteersInd
Paid Staff Or ManagementYes (true)PaidStaffOrManagementInd
Media AdvertisementsfalseMediaAdvertisementsInd
Mailings MembersfalseMailingsMembersInd
Publications Or BroadcastYes (true)PublicationsOrBroadcastInd
Publications Or Broadcast$239,637PublicationsOrBroadcastAmt
Grants Other OrganizationsfalseGrantsOtherOrganizationsInd
Direct Contact LegislatorsYes (true)DirectContactLegislatorsInd
Direct Contact Legislators$786,711DirectContactLegislatorsAmt
Rallies DemonstrationsYes (true)RalliesDemonstrationsInd
Rallies Demonstrations$90,017RalliesDemonstrationsAmt
Other ActivitiesYes (true)OtherActivitiesInd
Other Activities$558,530OtherActivitiesAmt
Total Lobbying Expenditures$1,674,895TotalLobbyingExpendituresAmt
Not Described Section501c3falseNotDescribedSection501c3Ind

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferenceSCHEDULE C, PART II-B, LINE 1FormAndLineReferenceDesc
ExplanationLLS IS A MEMBER OF A NUMBER OF COALITIONS INCLUDING FRIENDS OF CANCER RESEARCH, ALLIANCE FOR A STRONGER FDA, NATIONAL COALITION FOR CANCER RESEARCH, PATIENT ADVOCATE FOUNDATION, AMERICA ASSOCIATION FOR CANCER RESEARCH, CHILDREN'S CAUSE FOR CANCER ADVOCACY, THE CANCER LEADERSHIP COUNCIL AND THE ANTICANCER AGENT DEVELOPMENT AND VALIDATION WORKSHOP. LLS PARTNERS WITH A NUMBER OF LOBBYING FIRMS WHO WORK WITH OUR PUBLIC POLICY STAFF TO CARRY OUT OUR LOBBYING OBJECTIVES. LLS MOBILIZES PATIENT-ADVOCATES AND VOLUNTEERS TO ENGAGE WITH THEIR FEDERAL AND STATE LEGISLATORS THROUGH DIGITAL ADVOCACY - SENDING LETTERS; SHARING THEIR PERSONAL STORIES; SIGNING PETITIONS; AND ENCOURAGING THEIR LEGISLATORS TO SUPPORT LLS' POLICY PRIORITIES. IN CONJUNCTION WITH LLS EMPLOYEES, PATIENT-ADVOCATES ALSO VISIT THEIR LEGISLATORS IN THEIR LOCAL OFFICES, IN WASHINGTON, DC AND IN STATE CAPITOLS TO FURTHER LLS' POLICY AGENDA.ExplanationTxt

Schedule D IRS990ScheduleD

FieldValueIRS element (for citing)
Collection Used Pub ExhibitionYes (X)CollectionUsedPubExhibitionInd
Solicited Assets SalefalseSolicitedAssetsSaleInd

CY Endwmt Fund CYEndwmtFundGrp

FieldValueIRS element (for citing)
Beginning Year Balance$6,027,657BeginningYearBalanceAmt
Investment Earnings Or Losses$313,872InvestmentEarningsOrLossesAmt
Grants Or Scholarships-$215,000GrantsOrScholarshipsAmt
Administrative Expenses-$3,831AdministrativeExpensesAmt
End Year Balance$6,122,698EndYearBalanceAmt

CY Minus1 Yr Endwmt Fund CYMinus1YrEndwmtFundGrp

FieldValueIRS element (for citing)
Beginning Year Balance$6,000,186BeginningYearBalanceAmt
Investment Earnings Or Losses$482,520InvestmentEarningsOrLossesAmt
Grants Or Scholarships-$450,000GrantsOrScholarshipsAmt
Administrative Expenses-$5,049AdministrativeExpensesAmt
End Year Balance$6,027,657EndYearBalanceAmt

CY Minus2 Yr Endwmt Fund CYMinus2YrEndwmtFundGrp

FieldValueIRS element (for citing)
Beginning Year Balance$6,059,994BeginningYearBalanceAmt
Investment Earnings Or Losses$48,916InvestmentEarningsOrLossesAmt
Administrative Expenses-$9,992AdministrativeExpensesAmt
End Year Balance$6,000,186EndYearBalanceAmt

CY Minus3 Yr Endwmt Fund CYMinus3YrEndwmtFundGrp

FieldValueIRS element (for citing)
Beginning Year Balance$5,023,902BeginningYearBalanceAmt
Contributions$111,064ContributionsAmt
Investment Earnings Or Losses$938,068InvestmentEarningsOrLossesAmt
Administrative Expenses-$13,040AdministrativeExpensesAmt
End Year Balance$6,059,994EndYearBalanceAmt

CY Minus4 Yr Endwmt Fund CYMinus4YrEndwmtFundGrp

FieldValueIRS element (for citing)
Beginning Year Balance$4,481,610BeginningYearBalanceAmt
Investment Earnings Or Losses$563,236InvestmentEarningsOrLossesAmt
Administrative Expenses-$20,944AdministrativeExpensesAmt
End Year Balance$5,023,902EndYearBalanceAmt
FieldValueIRS element (for citing)
Prmnnt Endowment Balance EOY0.48000PrmnntEndowmentBalanceEOYPct
Term Endowment Balance EOY0.52000TermEndowmentBalanceEOYPct
Endowments Held Unrelated OrgfalseEndowmentsHeldUnrelatedOrgInd
Endowments Held Related OrgfalseEndowmentsHeldRelatedOrgInd

Leasehold Improvements LeaseholdImprovementsGrp

FieldValueIRS element (for citing)
Other Cost Or Other Basis$953,362OtherCostOrOtherBasisAmt
Depreciation$434,856DepreciationAmt
Book Value$518,506BookValueAmt

Equipment EquipmentGrp

FieldValueIRS element (for citing)
Other Cost Or Other Basis$27,556,719OtherCostOrOtherBasisAmt
Depreciation$11,922,469DepreciationAmt
Book Value$15,634,250BookValueAmt

Other Land Buildings OtherLandBuildingsGrp

FieldValueIRS element (for citing)
Other Cost Or Other Basis$2,689,855OtherCostOrOtherBasisAmt
Depreciation$2,433,003DepreciationAmt
Book Value$256,852BookValueAmt
FieldValueIRS element (for citing)
Total Book Value Land Buildings$16,409,608TotalBookValueLandBuildingsAmt

Other Securities OtherSecuritiesGrp (5 entries)

DescDescBook ValueBookValueAmtMethod ValuationMethodValuationCd
FUND OF HEDGE FUNDS- OPERATING$54,020,325F
LIMITED PARTNERSHIP EQUITIES-OPERATI$2,597,869F
FUND OF HEDGE FUNDS-ENDOWMENT$1,653,526F
457B PLAN$1,648,380F
LIMITED PARTNERSHIP EQUITIES-ENDOWME$295,908F
FieldValueIRS element (for citing)
Total Book Value Securities$60,216,008TotalBookValueSecuritiesAmt
Footnote TextYes (X)FootnoteTextInd
Total Rev Etc Audited Fincl Stmt$339,832,605TotalRevEtcAuditedFinclStmtAmt
Net Unrealized Gains Invst$6,349,371NetUnrealizedGainsInvstAmt
Donated Services And Use Fclts$10,982,172DonatedServicesAndUseFcltsAmt
Other Revenue$12,662,047OtherRevenueAmt
Revenue Not Reported$29,993,590RevenueNotReportedAmt
Revenue Subtotal$309,839,015RevenueSubtotalAmt
Investment Expenses Not Incld$198,971InvestmentExpensesNotIncldAmt
Other Revenues Not Included$58,001OtherRevenuesNotIncludedAmt
Revenue Not Reported Fincl Stmt$256,972RevenueNotReportedFinclStmtAmt
Total Revenue Per Form990$310,095,987TotalRevenuePerForm990Amt
Tot Expns Etc Audited Fincl Stmt$343,191,816TotExpnsEtcAuditedFinclStmtAmt
Donated Services Use Fclts$10,982,172DonatedServicesUseFcltsAmt
Other Expenses Included$15,210,333OtherExpensesIncludedAmt
Expenses Not Reported$26,192,505ExpensesNotReportedAmt
Expenses Subtotal$316,999,311ExpensesSubtotalAmt
Investment Expenses Not Incld2$198,971InvestmentExpensesNotIncld2Amt
Expenses Not Rpt Fincl Stmt$198,971ExpensesNotRptFinclStmtAmt
Total Expenses Per Form990$317,198,282TotalExpensesPerForm990Amt

Supplemental Information Detail SupplementalInformationDetail (7 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
SCHEDULE D, PAGE 2, PART III, LINE 4THE LLS COLLECTION IS OF PHOTOGRAPHS WHICH ARE USED FOR PUBLIC EXHIBITION AT FUNDRAISING EVENTS HELD TO SUPPORT LLS'S PROGRAMS.
SCHEDULE D, PAGE 2, PART V, LINE 4LLS'S ENDOWMENTS ARE INTENDED TO FUND RESEARCH AS WELL AS SUPPORT LLS'S PUBLIC EDUCATION PROGRAMS.
SCHEDULE D, PAGE 3, PART XLLS RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE TAX POSITIONS ARE MORE LIKELY THAN NOT TO BE SUSTAINED. INCOME GENERATED FROM ACTIVITIES UNRELATED TO LLS'S EXEMPT PURPOSE IS SUBJECT TO TAX UNDER INTERNAL REVENE CODE SECTION 511. LLS DID NOT RECOGNIZE ANY UNRELATED BUSINESS INCOME TAX LIABILITY FOR THE YEARS ENDED JUNE 30, 2014 AND 2013.
SCHEDULE D, PAGE 4, PART XI, LINE 2DLLS CANADA REVENUE 12,662,047
SCHEDULE D, PAGE 4, PART XI, LINE 4BLSRP CONTRIBUTION 58,002 ROUNDING -1
SCHEDULE D, PAGE 4, PART XII, LINE 2DLLS CANADA EXPENSES 11,853,901 FOREIGN CURRENCY TRANSALATION ADJUSTMENT 153,433 ROUNDING -4 WRITE-OFF OF CONTRIBUTIONS RECEIVABLE 3,507,289 GRANT REFUND EXPENSED IN PRIOR YEAR -304,286
SCHEDULE D, PAGE 4, PART XIIILLS MAINTAINS A SMALL PHOTOGRAPH COLLECTION FOR PUBLIC EXHIBITION WHICH HAS AN ESTIMATED VALUE OF BETWEEN 20,000 AND 50,000. AS THIS REPRESENTS A RELATIVELY SMALL PERCENTAGE OF LLS'S ASSETS, IT IS NOT SEPARATELY DISCLOSED IN THE FINANCIAL STATEMENTS OR FOOTNOTES.

Schedule F IRS990ScheduleF

FieldValueIRS element (for citing)
Grant Records MaintainedYes (true)GrantRecordsMaintainedInd

Account Activities Outside US AccountActivitiesOutsideUSGrp (4 entries)

RegionRegionTxtEmployeeEmployeeCntType Of Activities ConductedTypeOfActivitiesConductedTxtSpecific Services ProvidedSpecificServicesProvidedTxtRegion Total ExpendituresRegionTotalExpendituresAmtOfficesOfficesCnt
EAST ASIA4RESEARCH FUNDINGRESEARCH GRANTS$1,548,714
EUROPE13RESEARCH FUNDINGRESEARCH GRANTS$4,389,865
NORTH AMERICA13RESEARCH FUNDINGRESEARCH GRANTS$2,601,6037
CENTRAL AMERICA & CARIBBEANINVESTMENTSINVESTMENTS$25,156,350
FieldValueIRS element (for citing)
Subtotal Offices7SubtotalOfficesCnt
Subtotal Employees30SubtotalEmployeesCnt
Total Office7TotalOfficeCnt
Total Employee30TotalEmployeeCnt
Subtotal Spent$33,696,532SubtotalSpentAmt
Total Spent$33,696,532TotalSpentAmt

Grants To Org Outside US GrantsToOrgOutsideUSGrp (25 entries)

RegionRegionTxtPurpose Of GrantPurposeOfGrantTxtCash GrantCashGrantAmtManner Of Cash DisbursementMannerOfCashDisbursementTxtValuation Method UsedValuationMethodUsedDesc
EAST ASIA & PACIFICRESEARCH GRANT$55,000CHECKACCRUAL
EAST ASIA & PACIFICRESEARCH GRANT$1,250,000CHECKACCRUAL
EAST ASIA & PACIFICRESEARCH GRANT$200,000CHECKACCRUAL
EAST ASIA & PACIFICTHERAPY ACCELERATION$43,713CHECKFMV
EUROPERESEARCH GRANT$110,000WIREACCRUAL
EUROPERESEARCH GRANT$110,000WIREACCRUAL
EUROPERESEARCH GRANT$1,250,000CHECKACCRUAL
EUROPERESEARCH GRANT$398,748CHECKACCRUAL
EUROPETHERAPY ACCELERATION$750,000CHECKFMV
EUROPETHERAPY ACCELERATION$750,000CHECKFMV
EUROPETHERAPY ACCELERATION$9,554CHECKFMV
EUROPETHERAPY ACCELERATION$1,000,000CHECKFMV
EUROPETHERAPY ACCELERATION$11,563CHECKFMV
NORTH AMERICARESEARCH GRANT$200,000CHECKACCRUAL
NORTH AMERICARESEARCH GRANT$200,000CHECKACCRUAL
NORTH AMERICARESEARCH GRANT$200,000CHECKACCRUAL
NORTH AMERICARESEARCH GRANT$200,000CHECKACCRUAL
NORTH AMERICARESEARCH GRANT$200,000CHECKACCRUAL
NORTH AMERICARESEARCH GRANT$505,999CHECKACCRUAL
NORTH AMERICARESEARCH GRANT$200,000CHECKACCRUAL
NORTH AMERICARESEARCH GRANT$200,000CHECKACCRUAL
NORTH AMERICARESEARCH GRANT$300,000CHECKACCRUAL
NORTH AMERICARESEARCH GRANT$363,353CHECKACCRUAL
NORTH AMERICATHERAPY ACCELERATION$25,338CHECKFMV
NORTH AMERICATHERAPY ACCELERATION$5,132CHECKFMV
FieldValueIRS element (for citing)
Total Other Org20TotalOtherOrgCnt
Transfer To Foreign CorpYes (true)TransferToForeignCorpInd
Interest In Foreign TrustfalseInterestInForeignTrustInd
Foreign Corp OwnershipYes (true)ForeignCorpOwnershipInd
Passive Foreign Investmest CoYes (true)PassiveForeignInvestmestCoInd
Foreign PartnershipfalseForeignPartnershipInd
Boycott CountriesfalseBoycottCountriesInd

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
SCHEDULE F, PAGE 1, PART I, LINE 2FIDUCIARY RESPONSIBILITY AND TRANSPARENCY TO OUR DONORS IS A HIGH PRIORITY. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) PLACES CONSIDERABLE EMPHASIS ON THE OVERSIGHT OF GRANT SPENDING. TO ACCOMPLISH THIS WE REQUIRE THE SUBMISSION OF ANNUAL FINANCIAL REPORTS FOR EACH OF OUR ACTIVE GRANTS. THE REPORT MUST BE SIGNED BY THE FINANCIAL OFFICER AND/OR THE DESIGNATED OFFICIAL OF THE INSTITUTION HOSTING THE AWARD. AT THE END OF THE GRANT, WE REQUIRE A FINAL FINANCIAL REPORT THAT PROVIDES AN OVERVIEW OF ALL SPENDING THROUGH THE DURATION OF THE AWARD. WE REQUIRE SPECIFIC ACCOUNTING OF SPENDING ON PERSONNEL, CONSULTANTS,EQUIPMENT PURCHASES, SUPPLIES, TRAVEL, PATIENT CARE COSTS, ANIMAL CARE COSTS, AND ANY OTHER EXPENSE A GRANTEE MAY INCUR. WE HAVE SPECIFIC INSTRUCTIONS AND DOLLAR AMOUNT LIMITATIONS SET FOR MANY OF THESE CATEGORIES DEPENDING ON THE AWARD TYPE. FINANCIAL REPORTS ARE REVIEWED FOR NUMERICAL ACCURACY, ADHERENCE TO OUR GUIDELINES, AND FOR THE VERIFICATION OF APPROVAL FROM THE INSTITUTION'S FINANCIAL OFFICER. IF THE GRANTEE DOES NOT SUBMIT AN ANNUAL FINANCIAL REPORT BY THE DUE DATE OUTLINED IN THEIR CONTRACT, FUNDING IS SUSPENDED UNTIL LLS RECEIVES AND APPROVES THE DELINQUENT REPORT.
SCHEDULE F, PAGE 1, PART I, LINE 3EAST ASIA 1,548,714 0 EUROPE 4,389,865 0 NORTH AMERICA 2,601,603 0 CENTRAL AMERICA & CARIBBEAN 0 25,156,350

Schedule G IRS990ScheduleG

FieldValueIRS element (for citing)
Mail SolicitationsYes (X)MailSolicitationsInd
Email SolicitationsYes (X)EmailSolicitationsInd
Phone SolicitationsYes (X)PhoneSolicitationsInd
In Person SolicitationsYes (X)InPersonSolicitationsInd
Solicitation Of Non Govt GrantsYes (X)SolicitationOfNonGovtGrantsInd
Solicitation Of Govt GrantsYes (X)SolicitationOfGovtGrantsInd
Special Fundraising EventsYes (X)SpecialFundraisingEventsInd
Agrmt Prof Fundraising ActyYes (true)AgrmtProfFundraisingActyInd

Fundraiser Activity Info FundraiserActivityInfoGrp (8 entries)

Address Line1USAddress/AddressLine1CityUSAddress/CityStateUSAddress/StateZIP CodeUSAddress/ZIPCodeActivityActivityTxtFundraiser Control Of FundsFundraiserControlOfFundsIndRetained By ContractorRetainedByContractorAmtNet To OrganizationNetToOrganizationAmt
MAIL AMERICA COMMUNICATIONS INC
174 ELKTON FARM ROADFORESTVA24551DIRECT MAIfalse$3,745,937-$3,745,937
INFOCISION
325 SPRINSIDE DRIVEAKRONOH44333TELEMARKETfalse$1,728,035-$1,728,035
PARADYZ MATERA
5 HANOVER SQUARE 6TH FLOORNEW YORKNY10004DIRECT MAIfalse$1,320,036-$1,320,036
EPSILON
DALLAS 6021 CONNECTION DRIRVINGTX75039DIRECT MAIfalse$1,259,581-$1,259,581
DIRECT PRINT COMMUNICATIONS
201 EAST SANDPOINTE SUITE 400SANTA ANACA92707DIRECT MAIfalse$991,528-$991,528
THOMPSON HABIB & DENISON
80 HAYDEN AVENUE SUITE 300LEXINGTONMA02421DIRECT MAIfalse$672,496-$672,496
DONOR CARE CENTER INC
4345 STRAUSSSER ST NWNOTH CANTONOH44720TELEMARKETfalse$245,058-$245,058
BLACKBAUD
1800 DIAGONAL ROAD SUITE 400ALEXANDRIAVA22314DIRECT MAIfalse$101,502-$101,502
FieldValueIRS element (for citing)
Total Retained By Contractors$10,064,173TotalRetainedByContractorsAmt
Total Net To Organization-$10,064,173TotalNetToOrganizationAmt
All StatesAll StatesAllStatesCd

Fundraising Event Information FundraisingEventInformationGrp

FieldValueIRS element (for citing)
Name Of Event1NIKE WOMEN HALFNameOfEvent1Amt
Gross Receipts Event1$4,339,846GrossReceiptsEvent1Amt
Charitable Contri Event1$3,606,608CharitableContriEvent1Amt
Gross Revenue Event1$733,238GrossRevenueEvent1Amt
Other Direct Expenses Event1$733,238OtherDirectExpensesEvent1Amt
Name Of Event2NIKE WOMENS MARNameOfEvent2Amt
Gross Receipts Event2$8,884,317GrossReceiptsEvent2Amt
Charitable Contri Event2$6,946,142CharitableContriEvent2Amt
Gross Revenue Event2$1,938,175GrossRevenueEvent2Amt
Other Direct Expenses Event2$1,938,175OtherDirectExpensesEvent2Amt
Other Events Total1027OtherEventsTotalCnt
Gross Receipts Other Events$177,639,059GrossReceiptsOtherEventsAmt
Charitable Contri Other Events$153,037,578CharitableContriOtherEventsAmt
Gross Revenue Other Events$24,601,481GrossRevenueOtherEventsAmt
Oth Direct Expnss Other Events$24,601,481OthDirectExpnssOtherEventsAmt
Gross Receipts Total$190,863,222GrossReceiptsTotalAmt
Charitable Contributions Tot$163,590,328CharitableContributionsTotAmt
Gross Revenue Total Events$27,272,894GrossRevenueTotalEventsAmt
Oth Direct Expnss Total Events$27,272,894OthDirectExpnssTotalEventsAmt
Direct Expense Summary Events$27,272,894DirectExpenseSummaryEventsAmt

Gaming Information GamingInformationGrp

FieldValueIRS element (for citing)
Volunteer Labor BingofalseVolunteerLaborBingoInd
Volunteer Labor Pull TabsfalseVolunteerLaborPullTabsInd
Gross Revenue Other Gaming$795,990GrossRevenueOtherGamingAmt
Cash Prizes Other Gaming$7,653CashPrizesOtherGamingAmt
Non Cash Prizes Other Gaming$230,067NonCashPrizesOtherGamingAmt
Oth Direct Expnss Other Gaming$2,751OthDirectExpnssOtherGamingAmt
Volunteer Labor Other GamingYes (true)VolunteerLaborOtherGamingInd
Volunteer Labor Other Gaming0.71000VolunteerLaborOtherGamingPct
Gross Revenue Total Gaming$795,990GrossRevenueTotalGamingAmt
Cash Prizes Total Gaming$7,653CashPrizesTotalGamingAmt
Non Cash Prizes Total Gaming$230,067NonCashPrizesTotalGamingAmt
Oth Direct Expnss Total Gaming$2,751OthDirectExpnssTotalGamingAmt
Direct Expense Summary Gaming$240,471DirectExpenseSummaryGamingAmt
Net Gaming Income Summary$555,519NetGamingIncomeSummaryAmt
FieldValueIRS element (for citing)
LicensedYes (true)LicensedInd
License Suspended EtcfalseLicenseSuspendedEtcInd
Gaming With NonmembersfalseGamingWithNonmembersInd
Member Of Other EntityfalseMemberOfOtherEntityInd
Gaming Own Facility0.25000GamingOwnFacilityPct
Gaming Other Facility0.75000GamingOtherFacilityPct
Individual With BooksROSEMARIE LOFFREDOIndividualWithBooksNm

Persons With Books US Address PersonsWithBooksUSAddress

FieldValueIRS element (for citing)
Address Line11311 MAMARONECK AVENUEAddressLine1
CityWHITE PLAINSCity
StateNYState
ZIP Code10605ZIPCode
FieldValueIRS element (for citing)
Cntrct With3rd Prty For Game RevfalseCntrctWith3rdPrtyForGameRevInd
Gaming Manager PersonSEE SCHEDULE G PART IVGamingManagerPersonNm
Charitable Distribution RqrfalseCharitableDistributionRqrInd

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferenceSCHEDULE G, PART IVFormAndLineReferenceDesc
ExplanationSCHEDULE G PART I, LINE 2B LLS USED INFOCISION, MAIL AMERICA COMMUNICATIONS, DONOR CARE CENTER INC., EPSILON AND THOMPSON, HABIB & DENISON FOR ITS NATIONAL COMMUNITY CAMPAIGN AND DIRECT MAIL PROGRAMS. THESE PROGRAMS GENERATED GROSS RECEIPTS OF 19,483,579 DURING FISCAL YEAR 2014. LLS USED DIRECT PRINT COMMUNICATIONS, PARADYZ MATERA AND BLACKBAUD FOR ALL OF ITS OTHER FUNDRAISING EVENTS DURING FISCAL YEAR 2014. SCHEDULE G, PART III, LINE 9 - STATES WITH GAMING OPERATIONS ARIZONA, DISTRICT OF COLUMBIA, IOWA, KANSAS, LOUISIANA, MICHIGAN, NEVADA, NEW YORK, OHIO, OREGON, PENNSYLVANIA, RHODE ISLAND, TEXAS, WISCONSIN. SCHEDULE G, PART III, LINE 16 THE LEUKEMIA & LYMPHOMA SOCIETY DOES NOT HAVE AN OVERALL MANAGER FOR GAMING ACTIVITIES. EACH GAMING EVENT IS MANAGED LOCALLY BY THE SPECIFIC CHAPTER STAFF.ExplanationTxt

Schedule I IRS990ScheduleI

FieldValueIRS element (for citing)
Grant Records MaintainedYes (true)GrantRecordsMaintainedInd

Recipient Table RecipientTable (364 entries)

Address Line1USAddress/AddressLine1CityUSAddress/CityStateUSAddress/StateZIP CodeUSAddress/ZIPCodeRecipient EINRecipientEINIRC SectionIRCSectionDescCash GrantCashGrantAmtValuation Method UsedValuationMethodUsedDescPurpose Of GrantPurposeOfGrantTxt
ALBERT EINSTEIN COLLEGE OF MEDICINE
1300 MORRIS PARK AVEBRONXNY104611316242253$200,000ACCRUALRESEARCH GRANT
ALBERT EINSTEIN COLLEGE OF MEDICINE
1300 MORRIS PARK AVEBRONXNY104611316242253$200,000ACCRUALRESEARCH GRANT
ALBERT EINSTEIN COLLEGE OF MEDICINE
1300 MORRIS PARK AVEBRONXNY104611316242253$110,000ACCRUALRESEARCH GRANT
ALBERT EINSTEIN COLLEGE OF MEDICINE
1300 MORRIS PARK AVEBRONXNY104611316242253$200,000ACCRUALRESEARCH GRANT
ALBERT EINSTEIN COLLEGE OF MEDICINE
1300 MORRIS PARK AVEBRONXNY104611316242253$110,000ACCRUALRESEARCH GRANT
BAYLOR COLLEGE OF MEDICINE
1 BAYLOR PLAZAHOUSTONTX770307416138783$200,000ACCRUALRESEARCH GRANT
BAYLOR COLLEGE OF MEDICINE
1 BAYLOR PLAZAHOUSTONTX770307416138783$1,250,000ACCRUALRESEARCH GRANT
BECKMAN RESEARCH INSTITUTE OF THE C
1500 EAST DUARTE RDDUARTECA910109534322103$200,000ACCRUALRESEARCH GRANT
BECKMAN RESEARCH INSTITUTE OF THE C
1500 EAST DUARTE RDDUARTECA910109534322103$200,000ACCRUALRESEARCH GRANT
BECKMAN RESEARCH INSTITUTE OF THE C
1500 EAST DUARTE RDDUARTECA910109534322103$200,000ACCRUALRESEARCH GRANT
BETH ISRAEL DEACONESS MEDICAL CENTE
330 BROOKLINE AVENUEBOSTONMA022150421038813$110,000ACCRUALRESEARCH GRANT
BETH ISRAEL DEACONESS MEDICAL CENTE
330 BROOKLINE AVENUEBOSTONMA022150421038813$55,000ACCRUALRESEARCH GRANT
BETH ISRAEL DEACONESS MEDICAL CENTE
330 BROOKLINE AVENUEBOSTONMA022150421038813$200,000ACCRUALRESEARCH GRANT
BOARD OF REGENTS OF THE UNIVERSITY
4400 EMILE STOMAHANE681984700491233$200,000ACCRUALRESEARCH GRANT
BRANDEIS UNIVERSITY
415 SOUTH STWALTHAMMA024530421035523$55,000ACCRUALRESEARCH GRANT
BRIGHAM AND WOMEN'S HOSPITAL INC
75 FRANCIS STREETBOSTONMA021150423129093$190,657ACCRUALRESEARCH GRANT
BRIGHAM AND WOMEN'S HOSPITAL INC
75 FRANCIS STREETBOSTONMA021150423129093$110,000ACCRUALRESEARCH GRANT
BRIGHAM AND WOMEN'S HOSPITAL INC
75 FRANCIS STREETBOSTONMA021150423129093$110,000ACCRUALRESEARCH GRANT
BRIGHAM AND WOMEN'S HOSPITAL INC
75 FRANCIS STREETBOSTONMA021150423129093$1,250,000ACCRUALRESEARCH GRANT
STANFORD UNIVERSITY MEDICAL CENTER
291 CAMPUS DRSTANFORDCA943059411563653$65,000ACCRUALRESEARCH GRANT
STANFORD UNIVERSITY MEDICAL CENTER
291 CAMPUS DRSTANFORDCA943059411563653$55,000ACCRUALRESEARCH GRANT
STANFORD UNIVERSITY MEDICAL CENTER
291 CAMPUS DRSTANFORDCA943059411563653$65,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
500 PARNASSUS AVESAN FRANCISCOCA941439460364933$55,000ACCRUALRESEARCH GRANT
CA INSTITUTE OF TECHNOLOGY
1200 E CALIFORNIA BLVDPASADENACA911259516433073$55,000ACCRUALRESEARCH GRANT
CA INSTITUTE OF TECHNOLOGY
1200 E CALIFORNIA BLVDPASADENACA911259516433073$55,000ACCRUALRESEARCH GRANT
CASE WESTERN RESERVE UNIVERSITY - S
2109 ADELBERT RDCLEVELANDOH441063410189923$200,000ACCRUALRESEARCH GRANT
CHILDREN'S HOSPITAL BOSTON
300 LONGWOOD AVEBOSTONMA021150427744413$55,000ACCRUALRESEARCH GRANT
CHILDREN'S HOSPITAL BOSTON
300 LONGWOOD AVEBOSTONMA021150427744413$1,329,926ACCRUALRESEARCH GRANT
CHILDREN'S HOSPITAL BOSTON
300 LONGWOOD AVEBOSTONMA021150427744413$65,000ACCRUALRESEARCH GRANT
CHILDREN'S HOSPITAL BOSTON
300 LONGWOOD AVEBOSTONMA021150427744413$55,000ACCRUALRESEARCH GRANT
CHILDREN'S HOSPITAL BOSTON
300 LONGWOOD AVEBOSTONMA021150427744413$55,000ACCRUALRESEARCH GRANT
CHILDREN'S HOSPITAL BOSTON AND HARV
300 LONGWOOD AVEBOSTONMA021150427744413$55,000ACCRUALRESEARCH GRANT
CHILDRENS HOSPITAL LOS ANGELES
4650 SUNSET BLVDLOS ANGELESCA900279516909773$200,000ACCRUALRESEARCH GRANT
CHILDRENS HOSPITAL MEDICAL CENTER-C
3333 BURNET AVECINCINNATIOH452293108339363$110,000ACCRUALRESEARCH GRANT
CHILDRENS HOSPITAL MEDICAL CENTER-C
3333 BURNET AVECINCINNATIOH452293108339363$200,000ACCRUALRESEARCH GRANT
CHILDREN'S HOSPITAL PHILADELPHIA
34TH STREET AND CIVIC CENTER BOULEPHILADELPHIAPA191042313521663$400,000ACCRUALRESEARCH GRANT
CINCINNATI CHILDREN'S HOSPITAL MEDI
3333 BURNET AVECINCINNATIOH452293108339363$200,000ACCRUALRESEARCH GRANT
CINCINNATI CHILDREN'S HOSPITAL MEDI
3333 BURNET AVECINCINNATIOH452293108339363$200,000ACCRUALRESEARCH GRANT
CLEVELAND CLINIC FOUNDATION
9200 EUCLID AVECLEVELANDOH441959121530733$200,000ACCRUALRESEARCH GRANT
CLEVELAND CLINIC FOUNDATION
9200 EUCLID AVECLEVELANDOH441959121530733$200,000ACCRUALRESEARCH GRANT
COLUMBIA UNIVERSITY
116TH ST BROADWAYNEW YORKNY100271355980933$200,000ACCRUALRESEARCH GRANT
COLUMBIA UNIVERSITY
615 WEST 131 STREETNEW YORKNY100271355980933$400,000ACCRUALRESEARCH GRANT
COLUMBIA UNIVERSITY MEDICAL CENTER
630 W 168TH STREETNEW YORKNY100321355980933$110,000ACCRUALRESEARCH GRANT
COLUMBIA UNIVERSITY MEDICAL CENTER
630 W 168TH STREETNEW YORKNY100321355980933$110,000ACCRUALRESEARCH GRANT
COLUMBIA UNIVERSITY MEDICAL CENTER
630 W 168TH STREETNEW YORKNY100321355980933$55,000ACCRUALRESEARCH GRANT
COLUMBIA UNIVERSITY MEDICAL CENTER
630 W 168TH STREETNEW YORKNY100321355980933$55,000ACCRUALRESEARCH GRANT
COLUMBIA UNIVERSITY MEDICAL CENTER
630 W 168TH STREETNEW YORKNY100321355980933$55,000ACCRUALRESEARCH GRANT
COLUMBIA UNIVERSITY MEDICAL CENTER
630 W 168TH STREETNEW YORKNY100321355980933$200,000ACCRUALRESEARCH GRANT
COLUMBIA UNIVERSITY MEDICAL CENTER
630 W 168TH STREETNEW YORKNY100321355980933$200,000ACCRUALRESEARCH GRANT
COLUMBIA UNIVERSITY MEDICAL CENTER
630 W 168TH STREETNEW YORKNY100321355980933$200,000ACCRUALRESEARCH GRANT
COLUMBIA UNIVERSITY MEDICAL CENTER
630 W 168TH STREETNEW YORKNY100321355980933$55,000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$200,000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$200,000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$136,590ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$288,910ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE THE J
10 BROOKLINE PLACE WESTBROOKLINEMA024450422630403$55,000ACCRUALRESEARCH GRANT
DANA FARBER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$194,425FMVTHERAPY ACCELERATION
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$110,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$110,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$110,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$110,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$110,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$65,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$65,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$55,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$55,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$55,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$55,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$55,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$55,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$55,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$55,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$55,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$200,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$200,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$200,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$200,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$200,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$200,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$200,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$200,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$200,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$1,250,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$37,500ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$110,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$110,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVEBOSTONMA022150422630403$110,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVENUEBOSTONMA022150422630403$400,000ACCRUALRESEARCH GRANT
DUKE UNIVERSITY MEDICAL CENTER
324 BLACKWELL STREETDURHAMNC277085605321293$382,081ACCRUALRESEARCH GRANT
EMORY UNIVERSITY
201 DOWMAN DRATLANTAGA303225805662563$110,000ACCRUALRESEARCH GRANT
EMORY UNIVERSITY
PO BOX 935084ALTANTAGA311935805662563$450,000FMVTHERAPY ACCELERATION
FOX CHASE CANCER CENTER
333 COTTMAN AVEPHILADELPHIAPA191112320030723$200,000ACCRUALRESEARCH GRANT
FRED HUTCHINSON CANCER RESEARCH CEN
1100 FAIRVIEW AVE NSEATTLEWA981092371560713$65,000ACCRUALRESEARCH GRANT
FRED HUTCHINSON CANCER RESEARCH CEN
1100 FAIRVIEW AVE NSEATTLEWA981092371560713$55,000ACCRUALRESEARCH GRANT
FRED HUTCHINSON CANCER RESEARCH CEN
1100 FAIRVIEW AVE NSEATTLEWA981092371560713$55,000ACCRUALRESEARCH GRANT
FRED HUTCHINSON CANCER RESEARCH CEN
1100 FAIRVIEW AVE NSEATTLEWA981092371560713$200,000ACCRUALRESEARCH GRANT
FRED HUTCHINSON CANCER RESEARCH CEN
1100 FAIRVIEW AVE NSEATTLEWA981092371560713$200,000ACCRUALRESEARCH GRANT
FRED HUTCHINSON CANCER RESEARCH CEN
1100 FAIRVIEW AVE NSEATTLEWA981092371560713$100,000ACCRUALRESEARCH GRANT
FRED HUTCHINSON CANCER RESEARCH CEN
1100 FAIRVIEW AVE NSEATTLEWA981092371560713$110,000ACCRUALRESEARCH GRANT
GEORGIA CENTER FOR ONCOLOGY RESEARC
50 HURT PLAZAALTANTAGA303035711599793$190,494FMVTHERAPY ACCELERATION
H LEE MOFFITT CANCER CENTER & RESE
12902 USF MAGNOLIA DRTAMPAFL336125932386363$65,000ACCRUALRESEARCH GRANT
HARVARD MEDICAL SCHOOL
25 SHATTUCK STBOSTONMA021150421035803$65,000ACCRUALRESEARCH GRANT
HARVARD MEDICAL SCHOOL
25 SHATTUCK STBOSTONMA021150421035803$55,000ACCRUALRESEARCH GRANT
HARVARD MEDICAL SCHOOL
25 SHATTUCK STBOSTONMA021150421035803$55,000ACCRUALRESEARCH GRANT
HARVARD MEDICAL SCHOOL
25 SHATTUCK STBOSTONMA021150421035803$55,000ACCRUALRESEARCH GRANT
ICAHN SCHOOL OF MEDICINE AT MOUNT S
1428 MADISON AVENEW YORKNY100291361711973$110,000ACCRUALRESEARCH GRANT
IMMUNE DISEASE INSTITUTE (FKA) THE
3 BLACKFAN CIRBOSTONMA021150421035803$1,250,000ACCRUALRESEARCH GRANT
INDIANA UNIVERSITY
420 UNIVERSITY BLVDINDIANAPOLISIN462023560016733$110,000ACCRUALRESEARCH GRANT
JOAN & SANFORD I WEILL CORNELL MED
1300 YORK AVENEW YORKNY100651316239783$200,000ACCRUALRESEARCH GRANT
JOAN & SANFORD I WEILL MEDICAL COL
1300 YORK AVENEW YORKNY100651316239783$110,000ACCRUALRESEARCH GRANT
JOAN & SANFORD I WEILL MEDICAL COL
1300 YORK AVENEW YORKNY100651316239783$55,000ACCRUALRESEARCH GRANT
JOAN & SANFORD I WEILL MEDICAL COL
1300 YORK AVENEW YORKNY100651316239783$200,000ACCRUALRESEARCH GRANT
JOAN & SANFORD I WEILL MEDICAL COL
1300 YORK AVENEW YORKNY100651316239783$200,000ACCRUALRESEARCH GRANT
JOAN & SANFORD I WEILL MEDICAL COL
1300 YORK AVENEW YORKNY100651316239783$200,000ACCRUALRESEARCH GRANT
JOAN & SANFORD I WEILL MEDICAL COL
1300 YORK AVENEW YORKNY100651316239783$200,000ACCRUALRESEARCH GRANT
JOAN & SANFORD I WEILL MEDICAL COL
1300 YORK AVENEW YORKNY100651316239783$200,000ACCRUALRESEARCH GRANT
JOAN & SANFORD I WEILL MEDICAL COL
1300 YORK AVENEW YORKNY100651316239783$200,000ACCRUALRESEARCH GRANT
JOAN & SANFORD I WEILL MEDICAL COL
1300 YORK AVENEW YORKNY100651316239783$200,000ACCRUALRESEARCH GRANT
JOHNS HOPKINS UNIVERSITY
733 NORTH BROADWAYBALTIMOREMD212055205951103$65,000ACCRUALRESEARCH GRANT
JOHNS HOPKINS UNIVERSITY
733 NORTH BROADWAYBALTIMOREMD212055205951103$65,000ACCRUALRESEARCH GRANT
JOHNS HOPKINS UNIVERSITY
733 NORTH BROADWAYBALTIMOREMD212055205951103$277,750ACCRUALRESEARCH GRANT
JOHNS HOPKINS UNIVERSITY CENTR
12529 COLLECTIONS CENTER DRIVECHICAGOIL606935205951103$350,000FMVTHERAPY ACCELERATION
JOHNS HOPKINS UNIVERSITY CENTR
12529 COLLECTIONS CENTER DRIVECHICAGOIL606935205951103$700,000FMVTHERAPY ACCELERATION
JOHNS HOPKINS UNIVERSITY SCHOOL OF
733 N BROADWAYBALTIMOREMD212055205951103$110,000ACCRUALRESEARCH GRANT
JOHNS HOPKINS UNIVERSITY SCHOOL OF
733 N BROADWAYBALTIMOREMD212055205951103$110,000ACCRUALRESEARCH GRANT
JOHNS HOPKINS UNIVERSITY SCHOOL OF
733 N BROADWAYBALTIMOREMD212055205951103$200,000ACCRUALRESEARCH GRANT
JOHNS HOPKINS UNIVERSITY SCHOOL OF
733 N BROADWAYBALTIMOREMD212055205951103$200,000ACCRUALRESEARCH GRANT
LA JOLLA INSTITUTE FOR ALLERGY AND
9420 ATHENA CIRLA JOLLACA920373303286883$200,000ACCRUALRESEARCH GRANT
LUDWIG INSTITUTE FOR CANCER RESEARC
666 THIRD AVE 28TH FLNEW YORKNY100172371211313$55,000ACCRUALRESEARCH GRANT
MASSACHUSETTS GENERAL HOSPITAL
55 FRUIT STBOSTONMA021140415646553$65,000ACCRUALRESEARCH GRANT
MASSACHUSETTS GENERAL HOSPITAL
55 FRUIT STBOSTONMA021140415646553$110,000ACCRUALRESEARCH GRANT
MASSACHUSETTS GENERAL HOSPITAL
55 FRUIT STBOSTONMA021140415646553$65,000ACCRUALRESEARCH GRANT
MASSACHUSETTS GENERAL HOSPITAL
55 FRUIT STBOSTONMA021140415646553$200,000ACCRUALRESEARCH GRANT
MASSACHUSETTS GENERAL HOSPITAL
55 FRUIT STBOSTONMA021140415646553$110,000ACCRUALRESEARCH GRANT
MASSACHUSETTS INSTITUTE OF TECHNOLO
77 MASSACHUSETTS AVECAMBRIDGEMA021390421035943$55,000ACCRUALRESEARCH GRANT
MASSACHUSSETS GENERAL HOSPITAL
55 FRUIT STREETBOSTONMA021140415646553$356,484ACCRUALRESEARCH GRANT
MAYO CLINIC ARIZONA
13400 E SHEA BLVDSCOTTSDALEAZ852594160117023$200,000ACCRUALRESEARCH GRANT
MAYO CLINIC ARIZONA
13400 E SHEA BLVDSCOTTSDALEAZ852594160117023$110,000ACCRUALRESEARCH GRANT
MAYO CLINIC ARIZONA DBA MAYO CLI
13400 E SHEA BLVDSCOTTSDALEAZ852594160117023$200,000ACCRUALRESEARCH GRANT
MAYO CLINIC ARIZONA DBA MAYO CLI
13400 E SHEA BLVDSCOTTSDALEAZ852594160117023$200,000ACCRUALRESEARCH GRANT
MAYO CLINIC ARIZONA
13400 E SHEA BLVDSCOTTSDALEAZ852594160117023$110,000ACCRUALRESEARCH GRANT
MAYO CLINIC ARIZONA
13400 E SHEA BLVDSCOTTSDALEAZ852594160117023$200,000ACCRUALRESEARCH GRANT
MEMORIAL SLOAN KETTERING CANCER CEN
1275 YORK AVENUENEW YORKNY100651319242363$110,000ACCRUALRESEARCH GRANT
MEMORIAL SLOAN KETTERING CANCER CEN
1275 YORK AVENUENEW YORKNY100651319242363$65,000ACCRUALRESEARCH GRANT
MEMORIAL SLOAN KETTERING CANCER CEN
1275 YORK AVENUENEW YORKNY100651319242363$55,000ACCRUALRESEARCH GRANT
MEMORIAL SLOAN KETTERING CANCER CEN
1275 YORK AVENUENEW YORKNY100651319242363$55,000ACCRUALRESEARCH GRANT
MEMORIAL SLOAN-KETTERING CANCER CEN
1275 YORK AVENUENEW YORKNY100651319242363$110,000ACCRUALRESEARCH GRANT
MEMORIAL SLOAN-KETTERING CANCER CEN
1275 YORK AVENUENEW YORKNY100651319242363$200,000ACCRUALRESEARCH GRANT
MEMORIAL SLOAN-KETTERING CANCER CEN
1275 YORK AVENUENEW YORKNY100651319242363$200,000ACCRUALRESEARCH GRANT
MEMORIAL SLOAN-KETTERING CANCER CEN
1275 YORK AVENUENEW YORKNY100651319242363$200,000ACCRUALRESEARCH GRANT
MOFFITT CANCER CENTER AND RESEARCH
12902 USF MAGNOLIA DRTAMPAFL336125932386363$200,000ACCRUALRESEARCH GRANT
MOUNT SINAI SCHOOL OF MEDICINE
1428 MADISON AVENEW YORKNY100291361711973$110,000ACCRUALRESEARCH GRANT
MOUNT SINAI SCHOOL OF MEDICINE
1428 MADISON AVENEW YORKNY100291361711973$200,000ACCRUALRESEARCH GRANT
MPN RESEARCH FOUNDATION
180 N MICHIGAN AVENUE SUITE 1870CHICAGOIL606013643309673$400,000ACCRUALRESEARCH GRANT
NEW YORK UNIVERSITY SCHOOL OF MEDIC
550 1ST AVENUENEW YORKNY100161355623083$110,000ACCRUALRESEARCH GRANT
NEW YORK UNIVERSITY SCHOOL OF MEDIC
550 1ST AVENUENEW YORKNY100161355623083$65,000ACCRUALRESEARCH GRANT
NEW YORK UNIVERSITY SCHOOL OF MEDIC
550 1ST AVENUENEW YORKNY100161355623083$1,250,000ACCRUALRESEARCH GRANT
NEW YORK UNIVERSITY SCHOOL OF MEDIC
550 1ST AVENUENEW YORKNY100161355623083$65,000ACCRUALRESEARCH GRANT
NEW YORK UNIVERSITY SCHOOL OF MEDIC
550 FIRST AVE GBH-SC1-47NEW YORKNY100161355623083$100,000FMVTHERAPY ACCELERATION
NORTHWESTERN UNIVERSITY
633 CLARK STEVANSTONIL602083621678173$297,404ACCRUALRESEARCH GRANT
NORTHWESTERN UNIVERSITY - CHICAGO C
750 N LAKE SHORE DRCHICAGOIL606113621678173$55,000ACCRUALRESEARCH GRANT
NORTHWESTERN UNIVERSITY - CHICAGO C
750 N LAKE SHORE DRCHICAGOIL606113621678173$200,000ACCRUALRESEARCH GRANT
NORTHWESTERN UNIVERSITY - CHICAGO C
750 N LAKE SHORE DRCHICAGOIL606113621678173$200,000ACCRUALRESEARCH GRANT
NORTHWESTERN UNIVERSITY - CHICAGO C
750 N LAKE SHORE DRCHICAGOIL606113621678173$200,000ACCRUALRESEARCH GRANT
NORTHWESTERN UNIVERSITY - CHICAGO C
750 N LAKE SHORE DRCHICAGOIL606113621678173$1,250,000ACCRUALRESEARCH GRANT
OHIO STATE UNIVERSITY
281 W LANE AVECOLUMBUSOH432103160259863$300,000ACCRUALRESEARCH GRANT
OREGON HEALTH & SCIENCE UNIVERSITY
3181 SW SAM JACKSON PARK RDPORTLANDOR972399311761093$55,000ACCRUALRESEARCH GRANT
OREGON HEALTH & SCIENCE UNIVERSITY
3181 SW SAM JACKSON PARK RDPORTLANDOR972399311761093$1,250,000ACCRUALRESEARCH GRANT
OREGON HEALTH & SCIENCE UNIVERSITY
0690 SW BANCROFT STPORTLANDOR972399311761093$555,500FMVTHERAPY ACCELERATION
OREGON HEALTH & SCIENCE UNIVERSITY
0690 SW BANCROFT STPORTLANDOR972399311761093$1,111,000FMVTHERAPY ACCELERATION
PRESIDENT & FELLOWS OF HARVARD COLL
MASSACHUSETTS HALLCAMBRIDGEMA021380421035803$200,000ACCRUALRESEARCH GRANT
PRESIDENT & FELLOWS OF HARVARD COLL
MASSACHUSETTS HALLCAMBRIDGEMA021380421035803$65,000ACCRUALRESEARCH GRANT
PRESIDENT & FELLOWS OF HARVARD COLL
MASSACHUSETTS HALLCAMBRIDGEMA021380421035803$55,000ACCRUALRESEARCH GRANT
REGENTS OF THE UNIVERSITY OF MICHI
BOX 223131PITTSBURGHPA152513860063093$20,059FMVTHERAPY ACCELERATION
REGENTS OF THE UNIVERSITY OF MICHI
BOX 223131PITTSBURGHPA152513860063093$168,259FMVTHERAPY ACCELERATION
REGENTS OF THE UNIVERSITY OF MICHI
BOX 223131PITTSBURGHPA152513860063093$26,587FMVTHERAPY ACCELERATION
REGENTS OF THE UNIVERSITY OF MICHI
BOX 223131PITTSBURGHPA152513860063093$13,012FMVTHERAPY ACCELERATION
REGENTS OF THE UNIVERSITY OF MICHI
BOX 223131PITTSBURGHPA152513860063093$286,084FMVTHERAPY ACCELERATION
REGENTS OF THE UNIVERSITY OF MICHI
BOX 223131PITTSBURGHPA152513860063093$260,211FMVTHERAPY ACCELERATION
REGENTS OF THE UNIVERSITY OF MICHI
BOX 223131PITTSBURGHPA152513860063093$217,067FMVTHERAPY ACCELERATION
REGENTS OF THE UNIVERSITY OF MINNES
420 JOHH JOHNSTON HALL 101 PLEASAMINNEAPOLISMN554554160075133$200,000ACCRUALRESEARCH GRANT
REGENTS OF THE UNIVERSITY OF MINNES
420 JOHH JOHNSTON HALL 101 PLEASAMINNEAPOLISMN554554160075133$100,000ACCRUALRESEARCH GRANT
RHODE ISLAND HOSPITAL
593 EDDY STPROVIDENCERI029030502589543$65,000ACCRUALRESEARCH GRANT
SAINT LOUIS UNIVERSITY
221 N GRAND BLVDST LOUISMO631034306548723$200,000ACCRUALRESEARCH GRANT
SLOAN KETTERING INSTITUTE FOR CANCE
1275 YORK AVENUENEW YORKNY100651319242363$55,000ACCRUALRESEARCH GRANT
SLOAN-KETTERING INSTITUTE FOR CANCE
1275 YORK AVENUENEW YORKNY100651319242363$110,000ACCRUALRESEARCH GRANT
SLOAN-KETTERING INSTITUTE FOR CANCE
1275 YORK AVENUENEW YORKNY100651319242363$500,000ACCRUALRESEARCH GRANT
SLOAN-KETTERING INSTITUTE FOR CANCE
1275 YORK AVENUENEW YORKNY100651319242363$200,000ACCRUALRESEARCH GRANT
SLOAN-KETTERING INSTITUTE FOR CANCE
1275 YORK AVENUENEW YORKNY100651319242363$110,000ACCRUALRESEARCH GRANT
SLOAN-KETTERING INSTITUTE FOR CANCE
1275 YORK AVENUENEW YORKNY100651319242363$110,000ACCRUALRESEARCH GRANT
SLOAN-KETTERING INSTITUTE FOR CANCE
1275 YORK AVENUENEW YORKNY100651319242363$110,000ACCRUALRESEARCH GRANT
SLOAN-KETTERING INSTITUTE FOR CANCE
1275 YORK AVENUENEW YORKNY100651319242363$65,000ACCRUALRESEARCH GRANT
SLOAN-KETTERING INSTITUTE FOR CANCE
1275 YORK AVENUENEW YORKNY100651319242363$55,000ACCRUALRESEARCH GRANT
SLOAN-KETTERING INSTITUTE FOR CANCE
1275 YORK AVENUENEW YORKNY100651319242363$55,000ACCRUALRESEARCH GRANT
ST JUDE CHILDREN'S RESEARCH HOSPIT
262 DANNY THOMAS PLMEMPHISTN381056206460123$65,000ACCRUALRESEARCH GRANT
STANFORD UNIVERSITY
291 CAMPUS DRSTANFORDCA943059411563653$65,000ACCRUALRESEARCH GRANT
STANFORD UNIVERSITY
291 CAMPUS DRSTANFORDCA943059411563653$55,000ACCRUALRESEARCH GRANT
STANFORD UNIVERSITY
291 CAMPUS DRSTANFORDCA943059411563653$500,000ACCRUALRESEARCH GRANT
STANFORD UNIVERSITY
291 CAMPUS DRSTANFORDCA943059411563653$65,000ACCRUALRESEARCH GRANT
STANFORD UNIVERSITY
291 CAMPUS DRSTANFORDCA943059411563653$65,000ACCRUALRESEARCH GRANT
STANFORD UNIVERSITY
291 CAMPUS DRSTANFORDCA943059411563653$55,000ACCRUALRESEARCH GRANT
STANFORD UNIVERSITY
291 CAMPUS DRSTANFORDCA943059411563653$55,000ACCRUALRESEARCH GRANT
STANFORD UNIVERSITY
PO BOX 44253SAN FRANCISCOCA941449411563653$326,076FMVTHERAPY ACCELERATION
STOWERS INSTITUTE FOR MEDICAL RESEA
1000 E 50TH STKANSAS CITYMO641102029935093$55,000ACCRUALRESEARCH GRANT
SUNY UPSTATE MEDICAL UNIVERSITY
750 E ADAMS STSYRACUSENY132101660387033$110,000ACCRUALRESEARCH GRANT
THE BOARD OF REGENTS OF THE UNIVERS
1860 VAN HISE HALL 1220 LINDEN DRMADISONWI537063960064923$215,000ACCRUALRESEARCH GRANT
THE BOARD OF TRUSTEES OF THE LELAND
291 CAMPUS DRSTANFORDCA943059411563653$268,353ACCRUALRESEARCH GRANT
THE BOARD OF TRUSTEES OF THE LELAND
291 CAMPUS DRSTANFORDCA943059411563653$110,000ACCRUALRESEARCH GRANT
THE BOARD OF TRUSTEES OF THE UNIVER
700 S HALSTED ST 2029CHICAGOIL606073621771393$110,000ACCRUALRESEARCH GRANT
THE CHILDREN'S HOSPITAL OF PHILADEL
34TH ST CIVIC CENTER BLVDPHILADELPHIAPA191042322379323$110,000ACCRUALRESEARCH GRANT
THE CHILDREN'S HOSPITAL OF PHILADEL
34TH ST CIVIC CENTER BLVDPHILADELPHIAPA191042322379323$110,000ACCRUALRESEARCH GRANT
THE HOSPITAL FOR SPECIAL SURGERY
535 E 70TH STNEW YORKNY100211367147493$200,000ACCRUALRESEARCH GRANT
THE J DAVID GLADSTONE INSTITUTES
88 KEARNY ST SUITE 900SAN FRANCISCOCA941082372036663$100,000ACCRUALRESEARCH GRANT
THE OHIO STATE UNIVERSITY
281 W LANE AVECOLUMBUSOH432103160259863$65,000ACCRUALRESEARCH GRANT
THE OHIO STATE UNIVERSITY
281 W LANE AVECOLUMBUSOH432103160259863$55,000ACCRUALRESEARCH GRANT
THE OHIO STATE UNIVERSITY
281 W LANE AVECOLUMBUSOH432103160259863$1,250,000ACCRUALRESEARCH GRANT
THE OHIO STATE UNIVERSITY RESEARCH
281 W LANE AVECOLUMBUSOH432103160259863$200,000ACCRUALRESEARCH GRANT
THE PENNSYLVANIA STATE UNIVERSITY C
500 UNIVERSITY DRIVEHERSHEYPA170332460003763$200,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
2150 SHATTUCK AVE SUITE 300BERKELEYCA947049460021233$65,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
2150 SHATTUCK AVE SUITE 300BERKELEYCA947049460021233$65,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
2150 SHATTUCK AVE SUITE 300BERKELEYCA947049460021233$55,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
11000 KINROSS AVE SUITE 211LOS ANGELESCA900959560061433$65,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
11000 KINROSS AVE SUITE 211LOS ANGELESCA900959560061433$55,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
11000 KINROSS AVE SUITE 211LOS ANGELESCA900959560061433$200,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
9500 GILMAN DRLA JOLLACA920939560061443$110,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
9500 GILMAN DRLA JOLLACA920939560061443$110,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
9500 GILMAN DRLA JOLLACA920939560061443$110,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
9500 GILMAN DRLA JOLLACA920939560061443$55,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
9500 GILMAN DRLA JOLLACA920939560061443$1,250,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
9500 GILMAN DRLA JOLLACA920939560061443$55,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
500 PARNASSUS AVESAN FRANCISCOCA941439460364933$110,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
500 PARNASSUS AVESAN FRANCISCOCA941439460364933$65,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
500 PARNASSUS AVESAN FRANCISCOCA941439460364933$55,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
500 PARNASSUS AVESAN FRANCISCOCA941439460364933$200,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
500 PARNASSUS AVESAN FRANCISCOCA941439460364933$200,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
500 PARNASSUS AVESAN FRANCISCOCA941439460364933$110,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
500 PARNASSUS AVESAN FRANCISCOCA941439460364933$110,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
500 PARNASSUS AVESAN FRANCISCOCA941439460364933$110,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
500 PARNASSUS AVESAN FRANCISCOCA941439460364933$65,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
500 PARNASSUS AVESAN FRANCISCOCA941439460364933$55,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
500 PARNASSUS AVESAN FRANCISCOCA941439460364933$55,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
500 PARNASSUS AVESAN FRANCISCOCA941439460364933$55,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
500 PARNASSUS AVESAN FRANCISCOCA941439460364933$55,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
500 PARNASSUS AVESAN FRANCISCOCA941439460364933$55,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
500 PARNASSUS AVESAN FRANCISCOCA941439460364933$200,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
9500 GILMAN DRLA JOLLACA920939560061443$398,316ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
11000 KINROSS AVE SUITE 211LOS ANGELESCA900959560061433$110,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF MI
500 S STATE STANN ARBORMI481093860063093$110,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF MI
500 S STATE STANN ARBORMI481093860063093$110,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF MI
500 S STATE STANN ARBORMI481093860063093$110,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF MI
500 S STATE STANN ARBORMI481093860063093$110,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF MI
500 S STATE STANN ARBORMI481093860063093$200,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF MI
500 S STATE STANN ARBORMI481093860063093$200,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF MI
500 S STATE STANN ARBORMI481093860063093$200,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF MI
500 S STATE STANN ARBORMI481093860063093$110,000ACCRUALRESEARCH GRANT
THE ROCKEFELLER UNIVERSITY
1230 YORK AVENUENEW YORKNY100651316241583$65,000ACCRUALRESEARCH GRANT
THE ROCKEFELLER UNIVERSITY
1230 YORK AVENUENEW YORKNY100651316241583$55,000ACCRUALRESEARCH GRANT
THE ROCKEFELLER UNIVERSITY
1230 YORK AVENUENEW YORKNY100651316241583$55,000ACCRUALRESEARCH GRANT
THE ROCKEFELLER UNIVERSITY
1230 YORK AVENUENEW YORKNY100651316241583$55,000ACCRUALRESEARCH GRANT
THE ROCKEFELLER UNIVERSITY
1230 YORK AVENUENEW YORKNY100651316241583$55,000ACCRUALRESEARCH GRANT
THE ROCKEFELLER UNIVERSITY
1230 YORK AVENUENEW YORKNY100651316241583$55,000ACCRUALRESEARCH GRANT
THE SCRIPPS RESEARCH INSTITUTE
10550 N TORREY PINES RDLA JOLLACA920373304359543$110,000ACCRUALRESEARCH GRANT
THE TRUSTEES OF THE UNIVERSITY OF P
1 COLLEGE HALL ROOM 211PHILADELPHIAPA191042313526853$55,000ACCRUALRESEARCH GRANT
THE TRUSTEES OF THE UNIVERSITY OF P
1 COLLEGE HALL ROOM 211PHILADELPHIAPA191042313526853$65,000ACCRUALRESEARCH GRANT
THE TRUSTEES OF THE UNIVERSITY OF P
1 COLLEGE HALL ROOM 211PHILADELPHIAPA191042313526853$55,000ACCRUALRESEARCH GRANT
THE TRUSTEES OF THE UNIVERSITY OF P
1 COLLEGE HALL ROOM 211PHILADELPHIAPA191042313526853$200,000ACCRUALRESEARCH GRANT
THE TRUSTEES OF THE UNIVERSITY OF P
1 COLLEGE HALL ROOM 211PHILADELPHIAPA191042313526853$55,000ACCRUALRESEARCH GRANT
THE TRUSTEES OF THE UNIVERSITY OF P
1 COLLEGE HALL ROOM 211PHILADELPHIAPA191042313526853$1,250,000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF ALABAMA AT BIRMIN
1720 2ND AVE SBIRMINGHAMAL352336360053963$110,000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF CHICAGO
5801 S ELLIS AVENUECHICAGOIL606373621771393$200,000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF CHICAGO
5801 S ELLIS AVENUECHICAGOIL606373621771393$200,000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF NORTH CAROLINA AT
CB 1350 104 AIRPORT DR SUITE 220CHAPEL HILLNC275995660013933$200,000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF NORTH CAROLINA AT
104 AIRPORT DRIVECHAPEL HILLNC275995660013933$397,026ACCRUALRESEARCH GRANT
THE UNIVERSITY OF TEXAS MD ANDERSON
1515 HOLCOMBE BLVDHOUSTONTX770307460011183$200,000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF TEXAS MD ANDERSON
1515 HOLCOMBE BLVDHOUSTONTX770307460011183$200,000ACCRUALRESEARCH GRANT
TRUSTEES OF DARTMOUTH COLLEGE
6010 PARKHURST HALL SUITE 204HANOVERNH037550202221113$200,000ACCRUALRESEARCH GRANT
TUFTS MEDICAL CENTER
800 WASHINGTON STBOSTONMA021110434006173$300,000ACCRUALRESEARCH GRANT
UNIV OF TEXAS HEALTH SCIENCE CENTER
7703 FLOYD CURL DRSAN ANTONIOTX782297415860313$200,000ACCRUALRESEARCH GRANT
UNIVERSITY OF ARKANSAS FOR MEDICAL
4301 WEST MARKHAMLITTLE ROCKAR722057102369043$200,000ACCRUALRESEARCH GRANT
UNIVERSITY OF CA SAN DIEGO - HEALT
9500 GILMAN DR DEPT 0012LA JOLLACA920939560061443$55,000ACCRUALRESEARCH GRANT
UNIVERSITY OF CALIFORNIA SAN FRANCI
500 PARNASSUS AVESAN FRANCISCOCA941439460364933$110,000ACCRUALRESEARCH GRANT
UNIVERSITY OF CALIFORNIA SAN FRANCI
500 PARNASSUS AVESAN FRANCISCOCA941439460364933$200,000ACCRUALRESEARCH GRANT
UNIVERSITY OF COLORADO AT BOULDER
SPONSORED PROJECT ACCOUNTING PO BODENVERCO802918460005553$55,000ACCRUALRESEARCH GRANT
UNIVERSITY OF CONNECTICUT HEALTH CE
263 FARMINGTON AVEUEFARMINGTONCT060320607721603$326,189ACCRUALRESEARCH GRANT
UNIVERSITY OF FLORIDA
GRINTER HALL PO BOX 115500GAINESVILLEFL326115960020523$110,000ACCRUALRESEARCH GRANT
UNIVERSITY OF FLORIDA
GRINTER HALL PO BOX 115500GAINESVILLEFL326115960020523$200,000ACCRUALRESEARCH GRANT
UNIVERSITY OF FLORIDA
219 GINTER HALGAINESVILLEFL326115960020523$394,882ACCRUALRESEARCH GRANT
UNIVERSITY OF KANSAS MEDICAL CENTER
4350 SHAWNEE MISSION PARKWAYFAIRWAYKS662054812024023$84,948FMVTHERAPY ACCELERATION
UNIVERSITY OF MARYLAND BALTIMORE
620 W LEXINGTON STBALTIMOREMD212015260020333$200,000ACCRUALRESEARCH GRANT
UNIVERSITY OF MASSACHUSETTS MEDICAL
55 N LAKE AVENUEWORCESTERMA016550431673523$110,000ACCRUALRESEARCH GRANT
UNIVERSITY OF MASSACHUSETTS MEDICAL
55 N LAKE AVENUEWORCESTERMA016550431673523$55,000ACCRUALRESEARCH GRANT
UNIVERSITY OF MASSACHUSETTS MEDICAL
55 N LAKE AVENUEWORCESTERMA016550431673523$200,000ACCRUALRESEARCH GRANT
UNIVERSITY OF MASSACHUSETTS MEDICAL
55 N LAKE AVENUEWORCESTERMA016550431673523$110,000ACCRUALRESEARCH GRANT
UNIVERSITY OF MASSACHUSETTS MEDICAL
55 N LAKE AVENUEWORCESTERMA016550431673523$55,000ACCRUALRESEARCH GRANT
UNIVERSITY OF MICHIGAN
500 S STATE STANN ARBORMI481093860063093$241,290ACCRUALRESEARCH GRANT
UNIVERSITY OF MICHIGAN DEPARTMENT O
500 S STATE STANN ARBORMI481093860063093$110,000ACCRUALRESEARCH GRANT
UNIVERSITY OF MICHIGAN DEPARTMENT O
500 S STATE STANN ARBORMI481093860063093$200,000ACCRUALRESEARCH GRANT
UNIVERSITY OF MINNESOTA - TWIN CITI
420 JOHH JOHNSTON HALL 101 PLEASAMINNEAPOLISMN554554160075133$110,000ACCRUALRESEARCH GRANT
UNIVERSITY OF MINNESOTA TWIN CITIE
420 JOHH JOHNSTON HALL 101 PLEASAMINNEAPOLISMN554554160075133$200,000ACCRUALRESEARCH GRANT
UNIVERSITY OF NORTH CAROLINA AT CHA
CB 1350 104 AIRPORT DR SUITE 220CHAPEL HILLNC275995660013933$55,000ACCRUALRESEARCH GRANT
UNIVERSITY OF ROCHESTER
515 HYLAN BUILDING RC BOX 270140ROCHESTERNY146271607432093$200,000ACCRUALRESEARCH GRANT
UNIVERSITY OF TEXAS MD ANDERSON C
1515 HOLCOMBE BLVDHOUSTONTX770307460011183$200,000ACCRUALRESEARCH GRANT
UNIVERSITY OF TEXAS MD ANDERSON C
1515 HOLCOMBE BLVDHOUSTONTX770307460011183$500,000ACCRUALRESEARCH GRANT
UNIVERSITY OF TX MD ANDERSON CANC
1515 HOLCOMBE BLVDHOUSTONTX770307460011183$110,000ACCRUALRESEARCH GRANT
UNIVERSITY OF TX MD ANDERSON CANC
1515 HOLCOMBE BLVDHOUSTONTX770307460011183$110,000ACCRUALRESEARCH GRANT
UNIVERSITY OF TX MD ANDERSON CANC
1515 HOLCOMBE BLVDHOUSTONTX770307460011183$110,000ACCRUALRESEARCH GRANT
UNIVERSITY OF TX MD ANDERSON CANC
1515 HOLCOMBE BLVDHOUSTONTX770307460011183$110,000ACCRUALRESEARCH GRANT
UNIVERSITY OF TX MD ANDERSON CANC
1515 HOLCOMBE BLVDHOUSTONTX770307460011183$400,000ACCRUALRESEARCH GRANT
UNIVERSITY OF UTAH
201 PRESIDENTS CIRSALT LAKE CITYUT841128760005253$200,000ACCRUALRESEARCH GRANT
UNIVERSITY OF UTAH
201 PRESIDENTS CIRSALT LAKE CITYUT841128760005253$111,715ACCRUALRESEARCH GRANT
UNIVERSITY OF UTAH
201 PRESIDENTS CIRSALT LAKE CITYUT841128760005253$65,000ACCRUALRESEARCH GRANT
UNIVERSITY OF VIRGINIA
UNIVERSITY OF VIRGINIA SCHOOL OF MECHARLOTTESVILEVA229085416821763$100,000ACCRUALRESEARCH GRANT
UNIVERSITY OF VIRGINIA
UNIVERSITY OF VIRGINIA SCHOOL OF MECHARLOTTESVILEVA229085416821763$100,000ACCRUALRESEARCH GRANT
UNIVERSITY OF WASHINGTON
4333 BROOKLYN AVE 17TH FL UW TOWESEATTLEWA981059430794323$55,000ACCRUALRESEARCH GRANT
UNIVERSITY OF WASHINGTON
4333 BROOKLYN AVE 17TH FL UW TOWESEATTLEWA981059430794323$200,000ACCRUALRESEARCH GRANT
UNIVERSITY OF WISCONSIN-MADISON
21 N PARK ST SUITE 6401MADISONWI537153960064923$110,000ACCRUALRESEARCH GRANT
UT SOUTHWESTERN MEDICAL CENTER
5323 HARRY HINES BLVDDALLASTX753907560028683$110,000ACCRUALRESEARCH GRANT
UT SOUTHWESTERN MEDICAL CENTER
5323 HARRY HINES BLVDDALLASTX753907560028683$110,000ACCRUALRESEARCH GRANT
UT SOUTHWESTERN MEDICAL CENTER
5323 HARRY HINES BLVDDALLASTX753907560028683$55,000ACCRUALRESEARCH GRANT
UT SOUTHWESTERN MEDICAL CENTER
5323 HARRY HINES BLVDDALLASTX753907560028683$200,000ACCRUALRESEARCH GRANT
VANDERBILT UNIVERSITY MEDICAL CENTE
1211 MEDICAL CENTER DRNASHVILLETN372326204768223$110,000ACCRUALRESEARCH GRANT
VIRGINIA COMMONWEALTH UNIVERSITY
821 W FRANKLIN STRICHMONDVA232845460017583$200,000ACCRUALRESEARCH GRANT
WAKE FOREST UNIVERSITY HEALTH SCIEN
1 MEDICAL CENTER BLVDWINSTONSALEMNC271032238491993$200,000ACCRUALRESEARCH GRANT
WASHINGTON UNIVERSITY IN ST LOUIS
1 BROOKINGS DRST LOUISMO631304306536113$200,000ACCRUALRESEARCH GRANT
WASHINGTON UNIVERSITY OF ST LOUIS
660 S EUCLID AVEST LOUISMO631104306536113$110,000ACCRUALRESEARCH GRANT
WASHINGTON UNIVESITY SCHOOL OF MEDI
660 EUCLID AVEUNEST LOUISMO631109160015373$399,033ACCRUALRESEARCH GRANT
WHITEHEAD INSTITUTE FOR BIOMEDICAL
9 CAMBRIDGE CENTERCAMBRIDGEMA021420610434123$110,000ACCRUALRESEARCH GRANT
WHITEHEAD INSTITUTE FOR BIOMEDICAL
9 CAMBRIDGE CENTERCAMBRIDGEMA021420610434123$65,000ACCRUALRESEARCH GRANT
WHITEHEAD INSTITUTE FOR BIOMEDICAL
9 CAMBRIDGE CENTERCAMBRIDGEMA021420610434123$55,000ACCRUALRESEARCH GRANT
YALE UNIVERSITY
47 COLLEGE ST SUITE 216NEW HAVENCT065100606469733$55,000ACCRUALRESEARCH GRANT
YALE UNIVERSITY
47 COLLEGE ST SUITE 216NEW HAVENCT065100606469733$55,000ACCRUALRESEARCH GRANT
YALE UNIVERSITY
47 COLLEGE ST SUITE 216NEW HAVENCT065100606469733$100,000ACCRUALRESEARCH GRANT
YALE UNIVERSITY
47 COLLEGE ST SUITE 216NEW HAVENCT065100606469733$55,000ACCRUALRESEARCH GRANT
ACETYLON
SEAPORT CENTER 70 FARGO CENTERBOSTONMA02210263506788$250,000FMVTHERAPY ACCELERATION
BECKLOFF ASSOCIATES INC
3203 EAST SOLUTIONS CENTERCHICAGOIL60677480842223$44,891FMVTHERAPY ACCELERATION
BECKLOFF ASSOCIATES INC
3203 EAST SOLUTIONS CENTERCHICAGOIL60677480842223$11,053FMVTHERAPY ACCELERATION
BECKLOFF ASSOCIATES INC
3203 EAST SOLUTIONS CENTERCHICAGOIL60677480842223$17,505FMVTHERAPY ACCELERATION
BECKLOFF ASSOCIATES INC
3203 EAST SOLUTIONS CENTERCHICAGOIL60677480842223$10,392FMVTHERAPY ACCELERATION
BECKLOFF ASSOCIATES INC
3203 EAST SOLUTIONS CENTERCHICAGOIL60677480842223$16,427FMVTHERAPY ACCELERATION
BECKLOFF ASSOCIATES INC
3203 EAST SOLUTIONS CENTERCHICAGOIL60677480842223$25,000FMVTHERAPY ACCELERATION
BECKLOFF ASSOCIATES INC
3203 EAST SOLUTIONS CENTERCHICAGOIL60677480842223$100,000FMVTHERAPY ACCELERATION
BIO THERYX INC
20 CABIN RIDGE RDCHAPPAQUANY10514260501342$250,000FMVTHERAPY ACCELERATION
CELATOR PHARMACEUTICALS INC
200 PRINCETON SOUTH CORPORATE CENTEEWINGNJ08628202680869$267,145FMVTHERAPY ACCELERATION
CHARLES RIVER LABORATORIES INC
GPO BOX 27812NEW YORKNY10087760509980$36,053FMVTHERAPY ACCELERATION
CHARLES RIVER LABORATORIES INC
GPO BOX 27812NEW YORKNY10087760509980$42,750FMVTHERAPY ACCELERATION
CHARLES RIVER LABORATORIES INC
GPO BOX 27812NEW YORKNY10087760509980$72,050FMVTHERAPY ACCELERATION
CHARLES RIVER LABORATORIES INC
GPO BOX 27812NEW YORKNY10087760509980$20,816FMVTHERAPY ACCELERATION
CHARLES RIVER LABORATORIES INC
GPO BOX 27812NEW YORKNY10087760509980$6,210FMVTHERAPY ACCELERATION
CHARLES RIVER LABORATORIES INC
GPO BOX 27812NEW YORKNY10087760509980$12,820FMVTHERAPY ACCELERATION
CHARLES RIVER LABORATORIES INC
GPO BOX 27812NEW YORKNY10087760509980$13,877FMVTHERAPY ACCELERATION
CHARLES RIVER LABORATORIES INC
GPO BOX 27812NEW YORKNY10087760509980$35,658FMVTHERAPY ACCELERATION
CHARLES RIVER LABORATORIES INC
GPO BOX 27812NEW YORKNY10087760509980$614,490FMVTHERAPY ACCELERATION
CONSTELLATION PHARMACEUTICALS
215 FIRST STREETCAMBRIDGEMA02142261741721$1,000,000FMVTHERAPY ACCELERATION
CONSTELLATION PHARMACEUTICALS
215 FIRST STREETCAMBRIDGEMA02142261741721$250,000FMVTHERAPY ACCELERATION
CONSTELLATION PHARMACEUTICALS
215 FIRST STREETCAMBRIDGEMA02142261741721$1,500,000FMVTHERAPY ACCELERATION
KP PHARMACEUTICAL TECHNOLOGY
1212 W RAPPEL AVEBLOOMINGTONIN47404352025958$20,588FMVTHERAPY ACCELERATION
NANOSYN INC
3100 CENTRAL EXPRESSWAYSANTA CLARACA95051860909295$1,064,250FMVTHERAPY ACCELERATION
NANOSYN INC
3100 CENTRAL EXPRESSWAYSANTA CLARACA95051860909295$455,740FMVTHERAPY ACCELERATION
SHAPE PHARMACEUTICALS INC
47 THORNDIKE STREETCAMBRIDGEMA02141263714475$300,000FMVTHERAPY ACCELERATION
SHAPE PHARMACEUTICALS INC
47 THORNDIKE STREETCAMBRIDGEMA02141263714475$241,000FMVTHERAPY ACCELERATION
STEMLINE THERAPEUTICS INC
750 LEXINGTON AVENEW YORKNY10022450522567$1,000,000FMVTHERAPY ACCELERATION
VALOR BIOTHERAPEUTICS
8800 HSC PARKWAYBRYANTX77807461883738$400,000FMVTHERAPY ACCELERATION
VALOR BIOTHERAPEUTICS
8800 HSC PARKWAYBRYANTX77807461883738$400,000FMVTHERAPY ACCELERATION
VELESCO PHARMACEUTICAL SERVICE
46701 N COMMERCE CENTER DRIVEPLYMOUTHMI48170261330932$20,160FMVTHERAPY ACCELERATION
FieldValueIRS element (for citing)
Total501c3 Org109Total501c3OrgCnt
Total Other Org12TotalOtherOrgCnt

Grants Other Asst To Indiv In US GrantsOtherAsstToIndivInUSGrp (7 entries)

Grant TypeGrantTypeTxtRecipientRecipientCntCash GrantCashGrantAmt
PATIENT FINANCIAL AID25236$2,523,615
COPAY ASSISTANCE CLL2120$4,453,691
COPAY ASSISTANCE LYMPHOMA7905$17,443,678
COPAY ASSISTANCE MDS1478$3,320,299
COPAY ASSISTANCE MYELOMA6976$23,593,351
COPAY ASSISTANCE MANTEL161$435,000
PATIENT TRAVEL ASSISTNCE618$154,500

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferenceSCHEDULE I, PAGE 1, PART I, LINE 2FormAndLineReferenceDesc
ExplanationFIDUCIARY RESPONSIBILITY AND TRANSPARENCY TO OUR DONORS IS A HIGH PRIORITY. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) PLACES CONSIDERABLE EMPHASIS ON THE OVERSIGHT OF GRANT SPENDING. TO ACCOMPLISH THIS WE REQUIRE THE SUBMISSION OF ANNUAL FINANCIAL REPORTS FOR EACH OF OUR ACTIVE GRANTS. THE REPORT MUST BE SIGNED BY THE FINANCIAL OFFICER AND/OR THE DESIGNATED OFFICIAL OF THE INSTITUTION HOSTING THE AWARD. AT THE END OF THE GRANT, WE REQUIRE A FINAL FINANCIAL REPORT THAT PROVIDES AN OVERVIEW OF ALL SPENDING THROUGH THE DURATION OF THE AWARD. WE REQUIRE SPECIFIC ACCOUNTING OF SPENDING ON PERSONNEL, CONSULTANTS,EQUIPMENT PURCHASES, SUPPLIES, TRAVEL, PATIENT CARE COSTS, ANIMAL CARE COSTS, AND ANY OTHER EXPENSE A GRANTEE MAY INCUR. WE HAVE SPECIFIC INSTRUCTIONS AND DOLLAR AMOUNT LIMITATIONS SET FOR MANY OF THESE CATEGORIES DEPENDING ON THE AWARD TYPE. FINANCIAL REPORTS ARE REVIEWED FOR NUMERICAL ACCURACY, ADHERENCE TO OUR GUIDELINES, AND FOR THE VERIFICATION OF APPROVAL FROM THE INSTITUTION'S FINANCIAL OFFICER. IF THE GRANTEE DOES NOT SUBMIT AN ANNUAL FINANCIAL REPORT BY THE DUE DATE OUTLINED IN THEIR CONTRACT, FUNDING IS SUSPENDED UNTIL LLS RECEIVES AND APPROVES THE DELINQUENT REPORT. PATIENT FINANCIAL AID: THE LEUKEMIA AND LYMPHOMA SOCIETY (LLS) REGULARLY RECEIVES CALLS FROM PATIENTS WHO CANNOT MOVE FORWARD WITH THEIR POTENTIALLY LIFE-SAVING TREATMENTS BECAUSE THEY CANNOT AFFORD TO PAY FOR MANY EXPENSES RELATED TO THEIR TREATMENT. SOMETIMES PATIENTS HAVE TO CHOOSE BETWEEN BASIC NEEDS SUCH AS FOOD OR SHELTER AND THEIR HEALTH CARE TREATMENT EXPENSES. IN AN EFFORT TO ALLEVIATE SUCH HARDSHIPS, LLS HAS ESTABLISHED A PATIENT FINANCIAL AID PROGRAM THAT PROVIDES APPLICANTS, WHO RESIDE IN THE US AND HAVE A BLOOD CANCER DIAGNOSIS, A ONE-TIME ANNUAL STIPEND TO HELP DEFER SOME OF THESE EXPENSES. LLS ROUTINELY CONDUCTS AN OPERATIONAL AUDIT VERIFYING APPLICANTS ARE IN COMPLIANCE WITH PROGRAM GUIDELINES AND PROGRAM CRITERIA. CO-PAY ASSISTANCE: PATIENT APPLICATIONS ARE PROCESSED ON A FIRST COME, FIRST SERVED BASIS. ELIGIBLE PATIENTS MUST RESIDE IN THE UNITED STATES OR PUERTO RICO, HAVE A PROGRAM COVERED BLOOD CANCER DIAGNOSIS CONFIRMED BY A PHYSICIAN, MAINTAIN MEDICAL/PRESCRIPTION INSURANCE AND HAVE HOUSEHOLD INCOME AT OR BELOW 500% OF THE US FEDERAL POVERTY LEVEL AS ADJUSTED BY HOUSEHOLD SIZE AND COST OF LIVING INDEX. PATEINTS MUST PROVIDE PROOF OF INSURANCE AND INCOME. QUALIFYING PATIENTS ARE APPROVED FOR A TWELVE MONTH COVERAGE PERIOD. PATIENT TRAVEL ASSISTANCE: THE LEUKEMIA AND LYMPHOMA SOCIETY (LLS) REGULARLY RECEIVES CALLS FROM PATIENTS WHO CANNOT MOVE FORWARD WITH THEIR POTENTIALLY LIFE-SAVING TREATMENTS BECAUSE THEY CANNOT AFFORD TO PAY FOR TRANSPORTATION TO GET TO THEIR PROVIDERS, E.G. DOCTORS, HOSPITALS, TRANSPLANT CENTERS, AND RESEARCH OR CLINICAL TRIAL CENTERS. SOMETIMES PATIENTS HAVE TO TRAVEL OUT-OF-STATE TO GET THEIR PRESCRIBED AND RECOMMENDED TREATMENTS, OFTENTIMES RESULTING IN PATIENTS HAVING TO CHOOSE BETWEEN BASIC NEEDS SUCH AS FOOD OR SHELTER AND THEIR HEALTH CARE. IN AN EFFORT TO ALLEVIATE SUCH HARDSHIPS, LLS ESTABLISHED THE TRAVEL ASSISTANCE PROGRAM WHICH PROVIDES APPLICANTS, WHO ARE US CITIZENS OR PERMANENT RESIDENTS, HAVE AN ANNUAL INCOME AT OR BELOW 500% OF THE FEDERAL POVERTY LEVEL (FPL) AND HAVE A CONFIRMED BLOOD CANCER DIAGNOSIS, A ONE-TIME ANNUAL STIPEND TO HELP DEFER SOME OF THESE EXPENSES. LLS ROUTINELY CONDUCTS AN OPERATIONAL AUDIT VERIFYING APPLICANTS ARE IN COMPLIANCE WITH PROGRAM GUIDELINES AND PROGRAM CRITERIA.ExplanationTxt

Schedule J IRS990ScheduleJ

FieldValueIRS element (for citing)
Compensation CommitteeYes (X)CompensationCommitteeInd
Independent ConsultantYes (X)IndependentConsultantInd
Form990 Of Other OrganizationsYes (X)Form990OfOtherOrganizationsInd
Compensation SurveyYes (X)CompensationSurveyInd
Board Or Committee ApprovalYes (X)BoardOrCommitteeApprovalInd
Severance PaymentYes (true)SeverancePaymentInd
Supplemental Nonqual Rtr PlanYes (true)SupplementalNonqualRtrPlanInd
Equity Based Comp ArrngmfalseEquityBasedCompArrngmInd
Comp Based On Revenue Of Flng OrgfalseCompBasedOnRevenueOfFlngOrgInd
Comp Bsd On Rev Related OrgsfalseCompBsdOnRevRelatedOrgsInd
Comp Bsd Net Earns Flng OrgfalseCompBsdNetEarnsFlngOrgInd
Comp Bsd Net Earns Rltd OrgsfalseCompBsdNetEarnsRltdOrgsInd
Any Non Fixed PaymentsYes (true)AnyNonFixedPaymentsInd
Initial Contract ExceptionfalseInitialContractExceptionInd

Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (8 entries)

TitleTitleTxtBase Compensation Filing OrgBaseCompensationFilingOrgAmtOther Compensation Filing OrgOtherCompensationFilingOrgAmtDeferred Compensation Flng OrgDeferredCompensationFlngOrgAmtNontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmtTotal Compensation Filing OrgTotalCompensationFilingOrgAmtBonus Filing OrganizationBonusFilingOrganizationAmount
JOHN E WALTER
PRES&CEO TERM 2/2014$606,473$21,886$32,130$31,216$691,705
LOUIS J DEGENNARO
PRESIDENT & CEO$380,451$23,165$71,667$22,640$540,507$42,584
JAMES T NANGLE
SVP&CFO TERM 9/2013$155,599$252,803$15,606$26,767$450,775
LISA STOCKMON
EVP-CHIEF MKTG OFFIC$294,428$18,027$18,749$17,075$384,279$36,000
GEORGE J OMIROS
EVP-CHIEF CAMP&FIELD$299,361$20,357$25,500$19,753$379,971$15,000
MARK VELLECA
CHIEF POLICY & ADVOC$289,161$13,161$17,351$30,429$371,102$21,000
MARK ROITHMAYR
CHIEF DEVELOPMENT OF$301,719$18,995$25,806$346,520
BRIAN ROSEN
CHIEF POLICY & ADVOC$256,998$12,208$5,594$28,055$316,146$13,291

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
SCHEDULE J, PAGE 1, PART I, LINE 4LOUIS J. DEGENNARO 0 46,667 0 JAMES T. NANGLE 238,870 0 0
SCHEDULE J, PAGE 1, PART I, LINE 7BONUSES WERE PAID BASED ON THE ACHIEVEMENT OF GROSS REVENUE EXCEEDING BUDGTED GROSS REVENUE, EMPLOYEE INDIVIDUAL PERFORMANCE AND OTHER METRICS. BONUSES WERE CAPPED ACCORDING TO LLS'S POLICY. THESE AMOUNTS ARE REPORTED ON SCHEDULE J PART II, COLUMN (B) (II).

Schedule M IRS990ScheduleM

Securities Publicly Traded SecuritiesPubliclyTradedGrp

FieldValueIRS element (for citing)
Non Cash CheckboxYes (X)NonCashCheckboxInd
Contribution122ContributionCnt
Noncash Contributions Rpt F990$890,755NoncashContributionsRptF990Amt
Method Of Determining RevenuesMARKET VALUEMethodOfDeterminingRevenuesTxt

Food Inventory FoodInventoryGrp

FieldValueIRS element (for citing)
Non Cash CheckboxYes (X)NonCashCheckboxInd
Contribution51ContributionCnt

Other Non Cash Contri Table OtherNonCashContriTableGrp (3 entries)

Non Cash CheckboxNonCashCheckboxIndDescDescContributionContributionCnt
Yes (X)PRINTED ITEMS13
Yes (X)FURNITURE&EQUIP4
Yes (X)VARIOUS60
FieldValueIRS element (for citing)
Any Property That Must Be HeldfalseAnyPropertyThatMustBeHeldInd
Review Process Unusual NC GiftsYes (true)ReviewProcessUnusualNCGiftsInd
Third Parties UsedfalseThirdPartiesUsedInd

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
SCHEDULE M, PAGE 1, PART I, LINE 33LLS ONLY RECORDS DONATED SECURITIES AS REVENUE. ALL OTHER ITEMS FOR WHICH COLUMN A IS CHECKED ARE NOT RECORDED AS REVENUE OR EXPENSE BECAUSE THEY WOULD NOT HAVE BEEN PURCHASED HAD THEY NOT BEEN DONATED, AND ARE IMMATERIAL IN AMOUNT RELATIVE TO THE STATEMENTS OF LLS.
SCHEDULE M, PAGE 2, PART IIPART I, COLUMN (B) LLS IS REPORTING THE NUMBER OF CONTRIBUTIONS FOR EACH OF THE ITEMS IN PART I, NOT THE NUMBER OF INDIVIDUAL ITEMS.

Schedule O IRS990ScheduleO

Supplemental Information Detail SupplementalInformationDetail (17 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
FORM 990, PAGE 2, PART III, LINE 4ATO DATE, LLS HAS INVESTED ALMOST 1 BILLION IN RESEARCH AIMED AT HELPING ALL BLOOD CANCER PATIENTS LIVE BETTER, LONGER LIVES. WE WILL CONTINUE TO SUPPORT RESEARCH THROUGH OUR INNOVATIVE AND INTEGRATED FUNDING PROGRAMS, UNTIL EVERY PATIENT HAS A SAFE AND EFFECTIVE THERAPY. IN FISCAL YEAR 2014, LLS SUPPORTED RESEARCH IN THE U.S., CANADA AND 7 OTHER COUNTRIES WITH A TOTAL RESEARCH DISBURSEMENT OF APPROXIMATELY 78 MILLION. RESEARCH FUNDING WAS DISTRIBUTED ACROSS ALL BLOOD CANCERS. OUR CRITICAL ROLE LLS PROGRAMS ACCELERATE RELEVANT RESEARCH OUTCOMES BY: - BUILDING A FOCUSED RESEARCH WORK-FORCE: ASSURING THE NEXT ROUND OF BREAKTHROUGHS REQUIRES THAT YOUNG INVESTIGATORS BE ENCOURAGED TO WORK IN BLOOD CANCER RESEARCH FIELDS. - TURNING DISCOVERIES INTO NEW THERAPIES: FUNDAMENTAL NEW FINDINGS CAN BE TRANSLATED INTO SAFE AND EFFECTIVE TREATMENTS THAT CAN ULTIMATELY PROLONG AND ENHANCE PATIENT LIVES. - SUPPORTING SYNERGY: LARGE GRANTS AND CONTRACTS ENABLE SCIENTISTS IN ACADEMIA AND THE PRIVATE-SECTOR TO COLLABORATE, COMBINING RESOURCES AND EXPERTISE TO PRODUCE MORE AND FASTER ADVANCES. - FILLING A VOID: RESEARCH PROJECTS THAT ARE HIGH-RISK AND/OR ADDRESS RARE CANCERS ARE LESS LIKELY TO BE FUNDED BY GOVERNMENT AGENCIES OR FOR-PROFIT COMPANIES, BUT MAY PROVIDE IMPORTANT ADVANCES. - SPEEDING NEW TREATMENTS TO PATIENTS: PARTNERING WITH BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES CAN ADVANCE PROMISING THERAPIES THROUGH CLINICAL TESTING, FASTER. PAST ADVANCES MADE WITH LLS RESEARCH FUNDING GENEROUS DONORS HAVE HELPED LLS SUPPORT RESEARCH THAT HAS ALREADY BENEFITED BLOOD CANCER PATIENTS AND MANY OTHERS. ADVANCES INCLUDE: - MULTI-DRUG THERAPIES THAT ARE MORE EFFECTIVE THAN TREATMENTS WITH SINGLE ANTI-CANCER AGENTS, - BONE MARROW / STEM CELL TRANSPLANTATION AND SUPPORTIVE CARE TREATMENTS FOR PATIENTS WHO RELAPSE DESPITE THE BEST AVAILABLE THERAPY, - TESTS THAT DISTINGUISH SPECIFIC CHARACTERISTICS OF PARTICULAR BLOOD CANCERS FOR ACCURATE DIAGNOSIS OF CANCER SUBTYPES, AND FOR "RISK STRATIFICATION" TO SELECT AN OPTIMAL THERAPY. TARGETED THERAPY RESEARCH DISCOVERING THE MOLECULAR ABNORMALITIES THAT CAUSE PARTICULAR TYPES OF BLOOD CANCER HAS BEEN USEFUL IN DIAGNOSIS AND RISK STRATIFICATION, AND IN NEW "TARGETED DRUG" DEVELOPMENT. LLS-FUNDED INVESTIGATORS HAVE HELPED ADVANCE MOLECULARLY TARGETED TREATMENTS THAT CAN SELECTIVELY KILL BLOOD CANCER CELLS VERSUS NORMAL CELLS. MANY OF THESE NEW TREATMENTS BENEFIT NOT ONLY BLOOD CANCER PATIENTS, BUT ALSO PATIENTS WITH OTHER DISEASES. FOR EXAMPLE: - GLEEVEC IS FDA-APPROVED FOR PATIENTS OF ALL AGES WITH CHRONIC MYELOID LEUKEMIA (CML), AND IS ALSO APPROVED FOR PATIENTS WITH ONE FORM OF ACUTE LYMPHOID LEUKEMIA (ALL), MYELODYSPLASTIC SYNDROMES (MDS), MYELOPROLIFERATIVE DISORDERS AND RARE FORMS OF STOMACH AND SKIN CANCERS. RELATED DRUGS, SPRYCEL AND TASIGNA, ARE APPROVED FOR PATIENTS WHO DO NOT BENEFIT FROM GLEEVEC. ONE OR MORE OF THESE DRUGS ARE ALSO SHOWING PROMISE FOR PATIENTS WITH VARIOUS LYMPHOMAS, ACUTE MYELOID LEUKEMIA (AML), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND OTHER CANCERS, INCLUDING BRAIN, BREAST, HEAD-AND-NECK, LUNG, PANCREATIC, AND PROSTATE CANCERS, AND PATIENTS WITH OTHER DISEASES INCLUDING ALZHEIMER'S, ASTHMA AND PULMONARY HYPERTENSION. - RITUXAN WAS THE FIRST FDA-APPROVED, ANTI-CANCER ANTIBODY DRUG, DEVELOPED FOR PATIENTS WITH FORMS OF B-CELL NON-HODGKIN LYMPHOMA (NHL). IT IS NOW ALSO APPROVED FOR CLL PATIENTS AND AS A "MAINTENANCE" THERAPY FOR FOLLICULAR LYMPHOMA PATIENTS, AND SHOWING PROMISE FOR PATIENTS WITH ALL AND AFTER STEM CELL TRANSPLANTATION. IN ADDITION, IT IS APPROVED FOR TREATING PATIENTS WITH SEVERE RHEUMATOID ARTHRITIS AND TWO OTHER TYPES OF AUTOIMMUNE DISEASES. A RELATED ANTIBODY DRUG, ARZERRA, IS APPROVED FOR CLL PATIENTS AND SHOWING WIDER PROMISE. - VELCADE, THALIDOMID AND REVLIMID ARE FDA-APPROVED FOR PATIENTS WITH MYELOMA AND ARE ALSO HELPING SOME PATIENTS WITH HODGKIN LYMPHOMA AND NHL. KRYPOLIS WAS RECENTLY APPROVED FOR MYELOMA PATIENTS FOR WHOM AT LEAST TWO PRIOR THERAPIES WERE INSUFFICIENT. ONE OR MORE OF THESE DRUGS ARE NOW BEING TESTED FOR PATIENTS WITH T-CELL AND B-CELL FORMS OF LYMPHOMA, ACUTE LEUKEMIAS, AS WELL AS AIDS-RELATED KAPOSI SARCOMA AND BRAIN, BREAST, COLORECTAL, HEAD-AND-NECK, KIDNEY, LIVER, LUNG, OVARIAN AND PROSTATE CANCERS, AND ALZHEIMER'S DISEASE. - ISTODAX, ZOLINZA, DACOGEN AND VIDAZA TARGET SMALL CHEMICAL, "EPIGENETIC" CHANGES. THE FIRST TWO DRUGS ARE APPROVED FOR PATIENTS WITH PERIPHERAL T-CELL LYMPHOMAS; THE LATTER DRUGS ARE APPROVED FOR MDS PATIENTS. ONE OR MORE OF THESE DRUGS ARE BEING TESTED FOR PATIENTS WITH ALL, AML, CML, CLL, MYELOMA AND FORMS OF NHL, AFTER STEM CELL TRANSPLANTATION, AND FOR PATIENTS WITH BREAST, BRAIN, KIDNEY, COLORECTAL, HEAD-AND-NECK, LUNG, STOMACH, PROSTATE AND OVARIAN CANCERS, MELANOMA AS WELL AS SICKLE CELL DISEASE AND PERSISTENT HIV INFECTIONS. - ADCETRIS WAS APPROVED IN 2011, AND IN JANUARY 2012. IT IS AN ANTIBODY- DRUG CONJUGATE THAT COMBINES AN ANTI-CD30 ANTIBODY AND THE CYTOTOXIC DRUG MONOMETHYL AURISTATIN E (MMAE). IT IS AN ANTI-NEOPLASTIC AGENT USED IN THE TREATMENT OF HODGKIN LYMPHOMA AFTER FAILURE OF AUTOLOGOUS STEM CELL TRANSPLANT OR THOSE WHO ARE NOT ELIGIBLE FOR ASCT AFTER FAILURE OF AT LEAST 2 MUTIAGEN CHEMOTHERAPY REGIMENS. ADCETRIS WAS ALSO APPROVED FOR SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA WITH FAILURE OF AT LEAST ONE PRIOR TREATMENT. - GAZYVA IS A HUMANIZED MONOCLONAL ANTIBODY USED AS A COMBINATION TREATMENT WITH CHLORAMBUCIL TO TREAT PATIENTS WITH UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA. IT WAS APPROVED BY THE FDA IN NOVEMBER 2013 AND BY THE EHA IN JULY 2014. - IMBRUVICA IS AN ORAL SMALL MOLECULE INHIBITOR AGIANST BTK KINASE. IT WAS FIRST APPROVED BY THE US FDA ON NOVEMBER 13, 2013 FOR THE TREATMENT OF MANTLE CELL LYMPHOMA PATIENTS WHO HAVE RECIEVED AT LEAST ONE PRIOR TREATMENT. ON FEB. 12, 2014 THE US FDA EXPANDED THE APPROVED USE OF THE DRUG TO CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR TREATMENT. ADDITIONALLY, IT RECEIVED FURTHER EXPANSION TO TREAT 17P DELETION IN CLL WITH OR WITHOUT PRIOR THERAPY. - ZYDELIG IS AN ORAL SMALL MOLECULE INHIBITOR THAT BLOCKS THE DELTA ISOFORM OF THE ENZYME PHOSPHOINOSITIDE 3-KINASE. IT WAS APPROVED BY THE FDA IN JULY 2014 TO TREAT RELAPSED/REFRACTORY CLL IN COMBINATION WITH RITUXAN. IT WAS ALSO APPROVED TO USE AS A MONOTHERAPY FOR RELAPSED MANTLE CELL LYMPHOMA AND FOLLICULAR LYMPHOMA. OTHER ACTIVE RESEARCH DIRECTIONS LLS-FUNDED RESEARCHERS ARE ALSO EXPLORING OTHER AREAS OF RESEARCH THAT HOLD PROMISE FOR PATIENTS: - NOVEL STEM CELL TRANSPLANTATION PROCEDURES: THESE INCLUDE SO-CALLED "MINI" TRANSPLANTS THAT USE LESS TOXIC PRE-TRANSPLANT TREATMENTS AND ENGINEERED DONOR CELLS THAT HELP REDUCE POST-TRANSPLANT COMPLICATIONS, MAKING THESE POTENTIALLY CURATIVE TREATMENTS AVAILABLE TO MORE PATIENTS. - IMMUNOTHERAPIES: INCLUDING ANTIBODIES, VACCINES AND ENGINEERED IMMUNE CELLS, THESE TARGETED THERAPIES HELP A PATIENT'S IMMUNE SYSTEM FIGHT INFECTIONS AND KILL RESIDUAL CANCER CELLS, PROLONGING REMISSIONS, AND PERHAPS ONE DAY REPLACING TOXIC CHEMOTHERAPIES. - DIAGNOSTICS: NEW TECHNOLOGIES MAKE IT POSSIBLE TO CHARACTERIZE THE ABNORMALITIES IN INDIVIDUAL CANCER CASES IN MOLECULAR DETAIL. THIS INFORMATION CAN BE USED TO HELP CHOOSE THE BEST POSSIBLE TREATMENT FOR EACH PATIENT, ESPECIALLY AS MORE TARGETED THERAPIES BECOME AVAILABLE. - QUALITY OF LIFE RESEARCH: THESE STUDIES INCREASE OUR UNDERSTANDING OF HOW SPECIFIC TREATMENTS CAN CAUSE DEBILITATING SIDE-EFFECTS, INCLUDING LATE-EFFECTS, AND WHICH PATIENTS ARE AT RISK FOR DEVELOPING THESE COMPLICATIONS, SO THAT THEY CAN BE BETTER MANAGED OR EVEN PREVENTED. DRIVING RESEARCH TO ADDRESS UNMET MEDICAL NEEDS LLS CONTINUES TO SOLICIT AND SUPPORT RESEARCH FOCUSED ON IMPROVING BLOOD CANCER PATIENTS' QUALITY OF LIFE AFTER TODAY'S CURATIVE THERAPIES. ALSO IN 2014, FOR THE THIRD YEAR, LLS ACTIVELY RECRUITED RESEARCH PROPOSALS IN SIX OTHER UNDERDEVELOPED RESEARCH AREAS IN WHICH PROGRESS IS LIKELY TO IMPROVE OUTCOMES FOR PATIENTS WITH PARTICULARLY URGENT NEEDS. NEW RESEARCH IS FOCUSED ON: - DEVELOPMENT OF NOVEL THERAPEUTIC STRATEGIES FOR PATIENTS WITH NON- CUTANEOUS T-CELL LYMPHOPROLIFERATIVE DISORDERS - DEVELOP NOVEL TARGETED THERAPIES FOR CLL PATIENTS, WITH REAL CURATIVE POTENTIAL - DEVELOP NOVEL TREATMENT STRATEGEIES FOR MDS AND AML PATIENTS - DEVELOP NOVEL TARGETED THERAPIES FOR PATIENTS WITH HIGH-RISK MYELOMA - DEVELOPMENT OF NEW-TARGETED THERAPIES FOR INDOLENT LYMPHOMA PATIENTS - DEFINE GENETIC/MOLECULAR PREDISPOSITIONS TO LONG-TERM AND LATE-TERM EFFECTS ASSOCIATED WITH STANDARD THERAPIES IN PEDIATRIC ALL AND APPLY THIS INFORAMTION TO IMPROVE PATIENT OUTCOMES THE THERAPY ACCELERATION PROGRAM THIS STRATEGIC INITIATIVE WAS LAUNCHED IN 2007 TO MOVE NEW TREATMENTS AND DIAGNOSTICS THROUGH PRECLINICAL DEVELOPMENT AND CLINICAL TRIALS, FASTER. USING MILESTONE-DRIVEN CONTRACTS AND WORKING IN CONCERT WITH ACADEMIC INVESTIGATORS, MEDICAL CENTERS AND COMPANIES, LLS IS FURTHER BRIDGING THE GAP BETWEEN DISCOVERY AND HUMAN APPLI
FORM 990, PAGE 2, PART III, LINE 4BPROFESSIONAL AND PATIENT EDUCATION PROGRAMS, PUBLICATIONS AND THE LLS WEBSITE. A NUMBER OF RESOURCES ARE AVAILABLE IN SPANISH FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. LLS PUBLISHES AN ANNUAL COMPILATION OF DATA AVAILABLE FOR BLOOD CANCERS, INCLUDING THE ESTIMATED NUMBERS OF NEW BLOOD CANCER CASES AND DEATHS, THE MOST RECENT STATISTICS AVAILABLE FOR INCIDENCE, MORTALITY AND SURVIVAL; AND CURRENT AND ACCURATE INFORMATION ABOUT SYMPTOMS, RISK FACTORS AND TREATMENT. PUBLICATIONS AN EXTENSIVE CATALOG OF EDUCATION MATERIALS IS OFFERED FREE-OF-CHARGE TO PATIENTS AND HEALTHCARE PROFESSIONALS. EACH YEAR, LLS DISTRIBUTES BOOKLETS, BROCHURES, FACT SHEETS, EDUCATION PROGRAM TRANSCRIPTS AND DVDS THROUGH THE INFORMATION RESOURCE CENTER AND LLS CHAPTERS. MANY MATERIALS ARE ALSO AVAILABLE TO VIEW AND DOWNLOAD AT WWW.LLS.ORG/RESOURCECENTER. DOWNLOADABLE MATERIALS ARE AVAILABLE IN ENGLISH, SPANISH AND FRENCH. - 742,148 PRINTED BOOKLETS, BROCHURES, FACT SHEETS, EDUCATION PROGRAM TRANSCRIPTS AND DVDS DISTRIBUTED IN 2014. FINANCIAL ASSISTANCE IN 2014, A COMBINED 51,924,134 WAS DISBURSED TO PATIENTS THROUGH THE LLS PATIENT FINANCIAL AID (2,523,615),CO-PAY ASSISTANCE PROGRAMS (49,246,019) AND THE LLS PATIENT TRAVEL ASSISTANCE PROGRAM (154,500). PATIENT FINANCIAL ASSISTANCE PROGRAMS FOR MORE THAN 47 YEARS, LLS HAS HELPED PATIENTS DEMONSTRATING SIGNIFICANT NEED TO OBTAIN FINANCIAL ASSISTANCE TO COVER A PORTION OF THEIR TREATMENT COSTS. THE LLS PATIENT FINANCIAL ASSISTANCE PROGRAM PROVIDES A LIMITED AMOUNT OF FINANCIAL ASSISTANCE TO HELP PATIENTS WITH SIGNIFICANT FINANCIAL NEED AND WHO ARE UNDER A DOCTOR'S CARE FOR A CONFIRMED BLOOD CANCER DIAGNOSIS. PATIENT FINANCIAL ASSISTANCE FUNDS ARE SUBJECT TO AVAILABILITY. - 25,854 PATIENTS RECEIVED PATIENT FINANCIAL ASSISTANCE IN 2014. CO-PAY ASSISTANCE PROGRAM THIS CO-PAY ASSISTANCE PROGRAM HELPS PATIENTS WITH MANY KINDS OF BLOOD CANCERS MEET THEIR HEALTH INSURANCE OR MEDICARE PLAN PART B OR D PREMIUMS OR CO-PAYMENT OBLIGATIONS RELATED TO TREATING THEIR CANCER. PATIENTS WITH PRESCRIPTION DRUG COVERAGE, MEDICARE BENEFICIARIES UNDER MEDICARE PART B AND/OR MEDICARE PART D, MEDICARE SUPPLEMENTARY HEALTH INSURANCE OR MEDICARE ADVANTAGE SHOULD CHECK WITH LLS TO SEE IF THEY MEET ELIGIBILITY REQUIREMENTS TO RECEIVE FINANCIAL SUPPORT. CO-PAY ASSISTANCE IS SUBJECT TO FUND AVAILABILITY BY SPECIFIC BLOOD CANCER DIAGNOSIS. FOR MORE INFORMATION CALL, (877) LLS-COPAY (877) 557-2672 OR VISIT WWW.LLS.ORG/COPAY. - 18,640 PATIENTS RECEIVED LLS CO-PAY ASSISTANCE IN 2014 COMMUNITY PROGRAMS EACH LLS CHAPTER OFFICE IS STAFFED WITH A PATIENT SERVICES MANAGER (PSM) WHO OVERSEES SERVICES TO PATIENTS AND THEIR FAMILIES, CAREGIVERS AND HEALTHCARE PROFESSIONALS. PSMS ARE HEALTHCARE PROFESSIONALS, OFTEN WITH A BACKGROUND IN ONCOLOGY NURSING OR SOCIAL WORK. PSMS SERVE AS LIAISONS WITH COMMUNITY AND REGIONAL ONCOLOGY/HEMATOLOGY HEALTHCARE PROFESSIONALS AND TREATMENT CENTERS.COMMUNITY-BASED EDUCATION AND OUTREACH, SUPPORT AND PUBLIC POLICY AND ADVOCACY PROGRAMS ARE AVAILABLE. - 27,459 PATIENT AND CAREGIVER PARTICIPANTS ACROSS THE US IN 2014 - 10,798 HEALTHCARE PROFESSIONAL PARTICIPANTS ACROSS THE US IN 2014 PROGRAMS FOR CHILDREN AND YOUNG ADULTS THE TRISH GREENE BACK TO SCHOOL PROGRAM FOR CHILDREN WITH CANCER FOCUSES ON INCREASING COMMUNICATION AMONG HEALTHCARE PROFESSIONALS, PARENTS, PATIENTS AND SCHOOL PERSONNEL TO SUPPORT CHILDREN, ADOLESCENTS AND YOUNG ADULTS LIVING WITH CANCER. PRINTED LITERATURE, VIDEOS AND OTHER MATERIALS TO AID THE PROCESS ARE AVAILABLE IN COMMUNITIES THROUGHOUT THE US AND CANADA VIA LLS CHAPTER OFFICES. THE PROGRAM INCLUDES STAYING CONNECTED: FACILITATING THE LEARNING EXPERIENCE DURING AND AFTER CANCER TREATMENT. THIS EDUCATION PROGRAM FOR SCHOOL PERSONNEL, HEALTHCARE PROFESSIONALS AND PARENTS DESCRIBES PHYSICAL, COGNITIVE AND PSYCHOSOCIAL SHORT-AND LONG-TERM EFFECTS THAT CHILDREN, ADOLESCENTS AND YOUNG ADULTS MAY EXPERIENCE DURING AND AFTER TREATMENT. THE PROGRAM OFFERS GUIDANCE AND NUMEROUS RESOURCES TO HELP CHILDREN, ADOLESCENTS AND YOUNG ADULTS CONTINUE THEIR EDUCATION DURING AND AFTER TREATMENT. - 1,075 SCHOOL PERSONNEL, HEALTHCARE PROFESSIONALS AND PARENTS PARTICIPATED IN THE 22 STAYING CONNECTED PROGRAMS ACROSS THE US AND CANADA IN 2014. FAMILY SUPPORT GROUPS LLS HAS DEVELOPED 344 FAMILY SUPPORT GROUPS AT CHAPTERS THROUGHOUT THE US AND CANADA. LLS ALSO HAS 618 VOLUNTEER SUPPORT GROUP FACILITATORS WITH BACKGROUNDS IN ONCOLOGY NURSING OR SOCIAL WORK. GROUPS ARE GUIDED BY TWO VOLUNTEER ONCOLOGY HEALTH PROFESSIONALS, PROVIDING INFORMATION AND SUPPORT AND ENCOURAGING GREATER COMMUNICATION AMONG PATIENTS, FAMILIES, FRIENDS AND HEALTHCARE PROFESSIONALS. - 13,811 PARTICIPANTS IN FAMILY SUPPORT GROUPS ACROSS THE US IN 2014 PATTI ROBINSON KAUFMANN FIRST CONNECTION PROGRAM FIRST CONNECTION IS A PROGRAM THAT LINKS NEWLY DIAGNOSED PATIENTS TO A PEER VOLUNTEER WHO HAS EXPERIENCED A SIMILAR DIAGNOSIS. A TRAINED PATIENT-VOLUNTEER CURRENTLY IN REMISSION CONTACTS THE NEW PATIENT TO SHARE INFORMATION AND SUPPORT. THIS PROGRAM IS AVAILABLE THROUGH LLS CHAPTERS. - 5,616 FIRST CONNECTIONS ACROSS THE US IN 2014.
FORM 990, PAGE 2, PART III, LINE 4CNURSES AND HEALTH EDUCATORS WHO PROVIDE HELP WITH DISEASE, TREATMENT AND CLINICAL TRIAL INFORMATION AND SUPPORT. LLS INFORMATION SPECIALISTS CONDUCT CLINICAL-TRIAL SEARCHES TO HELP PATIENTS WORK WITH THEIR DOCTORS TO FIND OUT ABOUT SPECIFIC CLINICAL TRIALS. PATIENTS, FAMILIES AND HEALTHCARE PROFESSIONALS MAY SPEAK TO AN INFORMATION SPECIALIST AT (800) 955-4572 MONDAY THROUGH FRIDAY, 9 A.M. TO 9 P.M., ET, EMAIL INFOCENTER@LLS.ORG OR CHAT ONE-ON-ONE VIA THE LLS WEBSITE. THE INFORMATION RESOURCE CENTER OFFERS TRANSLATION SERVICES IN MORE THAN 165 LANGUAGES. - 48,326 INQUIRIES IN 2014 THE LLS WEBSITE THE LLS WEBSITE, WWW.LLS.ORG, FULFILLS A WIDE VARIETY OF EDUCATION AND INFORMATION NEEDS. VISITORS CAN PERSONALIZE THEIR WEB PAGES TO THEIR LOCATION TO KEEP CURRENT WITH DISEASE-SPECIFIC UPDATES AND COMMUNITY EDUCATION AND SUPPORT ACTIVITIES. THE WEBSITE PROVIDES ACCESS TO LLS PROGRAMS AND SERVICES, INCLUDING CO-PAY ASSISTANCE, THE MOST CURRENT AND ACCURATE INFORMATION AND STATISTICS, WEEKLY FACILITATED ONLINE CHATS, NATIONAL TELEPHONE AND WEB EDUCATION PROGRAMS, PUBLICATIONS IN ENGLISH, SPANISH AND FRENCH, AND CLINICAL-TRIAL SEARCHES VIA AN ONLINE CLINICAL- TRIAL SEARCH SERVICE THAT OFFERS PATIENTS AND CAREGIVERS IMMEDIATE ACCESS TO LISTINGS OF BLOOD CANCER CLINICAL TRIALS. PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS CAN INTERACT WITH LLS AND ONE ANOTHER THROUGH SOCIAL NETWORKING, PODCASTS AND ENEWSLETTERS. NATIONAL TELEPHONE/ WEB EDUCATION PROGRAMS LLS SPONSORS TELEPHONE AND WEB EDUCATION PROGRAMS FOR PATIENTS, CAREGIVERS, SURVIVORS AND HEALTHCARE PROFESSIONALS ABOUT LEUKEMIA, LYMPHOMA, MYELOMA AND MYELODYSPLASTIC SYNDROMES. IN 2014, 9 LLS NATIONAL EDUCATION PROGRAMS FEATURED DISEASE-SPECIFIC UPDATES AND INFORMATION ABOUT SUPPORT AND TREATMENT OPTIONS FROM WORLD RENOWNED CLINICAL EXPERTS. OPPORTUNITIES ARE PROVIDED TO ASK QUESTIONS OF EXPERTS DURING THESE PROGRAMS. THESE PROGRAMS OFFER CONTINUING EDUCATION CREDITS FOR NURSES AND SOCIAL WORKERS. LLS ALSO SPONSORS A RANGE OF PROFESSIONAL EDUCATION PROGRAMS. RECENT PROGRAMS EXPLORED THE ADMINISTRATION AND MANAGEMENT OF CURRENT THERAPIES FOR HEMATOLOGIC MALIGNANCIES AND COMMUNICATION AMONG PRIMARY CARE PROVIDERS AND HEMATOLOGISTS/ONCOLOGISTS IN MANAGING PATIENTS WITH HEMATOLOGIC CANCER. UPCOMING PROGRAMS ARE POSTED AT WWW.LLS.ORG/PROGRAMS AND ARCHIVES OF PAST PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/PASTPROGRAMS. PROFESSIONAL EDUCATION PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/PROFESSIONALED. LLS ALSO OFFERS DISEASE-SPECIFIC WEBCASTS PRESENTED BY WORLD RENOWNED CLINICAL EXPERTS. THESE CAN BE ACCESSED AT WWW.LLS.ORG/WEBCASTS.
FORM 990, PAGE 2, PART III, LINE 4DD) PROFESSIONAL EDUCATION: LLS SERVES THE EDUCATIONAL NEEDS OF THE MEDICAL AND RESEARCH COMMUNITY THROUGH A NUMBER OF PROFESSIONAL EDUCATION SYMPOSIA OFFERED THROUGHOUT THE YEAR. THE EDUCATIONAL PROGRAM OFFERS VARYING FORMATS TO FACILITATE THE EXCHANGE OF INFORMATION AND IDEAS ON THE NEWEST DEVELOPMENTS IN CANCER RESEARCH AND TREATMENT.
FORM 990, PART V, LINE 4BCANADA
FORM 990, PAGE 6, PART VI, LINE 4IN 2013, THE LLS BOARD OF DIRECTORS (BOD) AND THE BOARD OF REPRESENTATIVES (BOR) AUTHORIZED CHANGES TO THE CHAPTERS' INVOLVEMENT IN THE LLS GOVERNANCE. PURSUANT TO THE CHANGES, THE LLS BYLAWS WERE AMENDED IN JANUARY 2014 TO REFLECT THAT THE CHAPTERS, ACTING THROUGH THE CHAPTER CHAIR ASSEMBLY WILL REPLACE THE BOR AND WILL RETAIN OVERSIGHT OVER THE LLS ACTIVITIES AND PROGRAMS AT THE CHAPTER LEVEL. ALL OTHER VOTING RIGHTS AFFORDED TO MEMBERS UNDER THE NEW YORK NOT-FOR-PROFIT CORPORATION LAW (NPCL), INCLUDING THE RIGHT TO ELECT THE LLS ELECTED DIRECTORS, WILL NOW BE VESTED IN A SECOND CLASS OF MEMBERS COMPRISED OF THE LLS BOARD OF DIRECTORS. IN ADDITION, THE LLS BYLAWS WERE AMENDED TO REFLECT THE REQUIREMENTS OF THE NEW YORK NON-PROFIT REVITALIZATION ACT OF 2013. THE ACT REQUIRES LLS TO EXERCISE INCREASED OVERSIGHT OF ITS AUDIT AS WELL AS ITS ACCOUNTING AND FINANCIAL REPORTING PROCESSES. THE AMENDMENT INCLUDES ADDITIONAL DUTIES THAT THE AUDIT COMMITTEE MUST CARRY OUT TO COMPLY WITH THE ACT.
FORM 990, PAGE 6, PART VI, LINE 6THE MEMBERS OF LLS CONSIST OF ONE ELECTED REPRESENTATIVE FROM EACH CHAPTER.
FORM 990, PAGE 6, PART VI, LINE 7ATHE LLS BOARD OF DIRECTORS ELECT THE ELECTED DIRECTORS AND HAVE ALL OF THE OTHER VOTING RIGHTS AFFORDED TO MEMBERS UNDER THE NEW YORK NOT-FOR-PROFIT CORPORATION LAW.
FORM 990, PAGE 6, PART VI, LINE 7BSIGNIFICANT DECISIONS AFFECTING THE CHAPTERS REQUIRE AN APPROVING VOTE BY THE CHAPTER DELEGATES. DECISIONS NOT SIGNIFICANTLY AFFECTING THE CHAPTERS DO NOT REQUIRE APPROVAL FROM THE CHAPTER DELEGATES.
FORM 990, PAGE 6, PART VI, LINE 11BTHE FORM 990 WAS PREPARED BY THE LLS FINANCE DEPARTMENT AND WAS REVIEWED BY THE CAO & CFO, SR. VICE PRESIDENT OF FINANCE, AND KPMG FOR COMMENT AND SUGGESTED REVISIONS. THE FORM 990 WAS THEN PROVIDED TO THE AUDIT COMMITTEE, WHICH IS A COMMITTEE OF THE BOARD OF DIRECTORS. THE AUDIT COMMITTEE REVIEWED THE 990 AND PROVIDED INPUT PRIOR TO FILING. THE 990 WAS POSTED TO THE BOARD BOOKS SITE AND WAS FORMALLY APPROVED BY THE AUDIT COMMITTEE ON JANUARY 29, 2015 AND AT THE FULL BOARD MEETING ON JANUARY 30, 2015.
FORM 990, PAGE 6, PART VI, LINE 12CALL EMPLOYEES, BOARD OF DIRECTORS MEMBERS, BOARD OF REPRESENTATIVES MEMBERS, CHAPTER BOARD MEMBERS, FAMILY SUPPORT GROUP FACILITATORS, AND TNT COACHES ARE REQUIRED TO REVIEW THE CONFLICT OF INTEREST POLICY ON AN ANNUAL BASIS AND SUBMIT A SIGNED FORM ACKNOWLEDGING THAT THEY HAVE REVIEWED THE POLICY AND DISCLOSED ANY CONFLICTS OF INTEREST. ALL FORMS ARE COLLECTED AND THE AUDIT COMMITTEE REVIEWS ANY FORMS DISCLOSING A POSSIBLE CONFLICT OF INTEREST AND DETERMINES WHETHER OR NOT A CONFLICT EXISTS. PART VI, LINE 12 C: ALL EMPLOYEES, BOARD OF DIRECTORS MEMBERS, BOARD OF REPRESENTATIVES ARE RECUSED FROM ANY DISCUSSION WHERE A CONFLICT OF INTEREST EXISTS. ANY QUESTIONS REGARDING COI WILL GO TO THE AUDIT COMMITTEE.
FORM 990, PAGE 6, PART VI, LINE 15ATHE EXECUTIVE COMMITTEE, COMPRISED OF INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS, REVIEWS AND MONITORS THE CHIEF EXECUTIVE OFFICER'S PERFORMANCE AND COMPENSATION. THE COMMITTEE OBTAINED A SURVEY OF OTHER NOT-FOR-PROFIT ORGANIZATIONS' COMPENSATION RANGES AND SET THE CHIEF EXECUTIVE'S SALARY COMMENSURATELY. THE MOST RECENT SURVEY WAS CONDUCTED IN 2013. THE REVIEW WAS DOCUMENTED IN THE EXECUTIVE COMMITTEE'S MINUTES.
FORM 990, PAGE 6, PART VI, LINE 15BTHE EXECUTIVE COMMITTEE, COMPRISED OF INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS, REVIEWED A SURVEY OF OTHER NOT-FOR-PROFIT ORGANIZATIONS' COMPENSATION RANGES IN 2013 AND COMPARED THIS TO THE OTHER OFFICER'S SALARY AND DETERMINED THAT IT WAS APPROPRIATE. THE REVIEW WAS DOCUMENTED IN THE EXECUTIVE COMMITTEE'S MINUTES.
FORM 990, PAGE 6, PART VI, LINE 17ILLINOIS, INDIANA, KANSAS, KENTUCKY, LOUISIANA, MASSACHUSETTS, MARYLAND, MAINE, MICHIGAN, MINNESOTA, MISSOURI, MISSISSIPPI, NEW HAMPSHIRE, NEW JERSEY, NEW MEXICO, NEBRASKA, NEW YORK, OHIO, OKLAHOMA, OREGON, PENNSYLVANIA, PUERTO RICO, RHODE ISLAND, SOUTH CAROLINA, TENNESSEE, UTAH, VIRGINIA, WASHINGTON, WISCONSIN, WEST VIRGINIA
FORM 990, PAGE 6, PART VI, LINE 19THE LEUKEMIA & LYMPHOMA SOCIETY, INC. MAKES ITS ANNUAL FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC ON ITS WEBSITE AT WWW.LLS.ORG. ITS GOVERNING DOCUMENTS ARE MADE AVAILABLE, WHEN CHANGES ARE MADE, AS PART OF THE 990 AVAILABLE FOR PUBLIC INSPECTION. ANY IDENTIFIED CONFLICTS OF INTEREST ARE DISCLOSED IN THE 990.
FORM 990, PART XI, LINE 9LLS CANADA REVENUE 12,662,047 LSRP CONTRIBUTION -58,002 ROUNDING 1 LLS CANADA EXPENSES -11,853,901 FOREIGN CURRENCY TRANSALATION ADJUSTMENT -153,433 ROUNDING 4 WRITE-OFF OF CONTRIBUTIONS RECEIVABLE -3,507,289 GRANT REFUND EXPENSED IN PRIOR YEAR 304,286
FORM 990, PART XI, LINE 9CHANGE IN NET ASSETS LLS CANADA -724,448 LSRP CONNTRIBUTION 58,002 FINANCIAL STATEMENT ROUNDING -101 FOREIGN CURRENCY TRANSLATION 153,433 UNREALIZED CHANGE ON INVESTMENTS -6,349,371 WRITE-OFF OF CONTRIBUTIONS RECEIVABLES 3,507,289 GRANT REFUND EXPENSED IN PRIOR YEAR -304,286 CHANGE IN NET ASSETS PER FORM 990 (PART XI, LINE 3) -7,102,295

Schedule R IRS990ScheduleR

Id Related Tax Exempt Org IdRelatedTaxExemptOrgGrp (3 entries)

Address Line1ForeignAddress/AddressLine1CityForeignAddress/CityCountryForeignAddress/CountryPostal CodeForeignAddress/PostalCodePrimary ActivitiesPrimaryActivitiesTxtLegal Domicile Foreign CountryLegalDomicileForeignCountryCdBusiness Name Line1DirectControllingEntityName/BusinessNameLine1Controlled OrganizationControlledOrganizationIndAddress Line1USAddress/AddressLine1CityUSAddress/CityStateUSAddress/StateZIP CodeUSAddress/ZIPCodeEINEINLegal Domicile StateLegalDomicileStateCdExempt Code SectionExemptCodeSectionTxtPublic Charity StatusPublicCharityStatusTxt
THE LLS OF CANADA
804 2 LANSING SQUARETORONTOCAM2J4P8PART VIICALLS INCYes (true)
THE LLS RESEARCH PROGRAMS INC
PART VIILLS INCYes (true)1311 MAMARONECK AVENUEWHITE PLAINSNY10605133470494DE501C311B
THE LLS RESEARCH FOUNDATION
PART VIILLS INCYes (true)1311 MAMARONECK AVENUEWHITE PLAINSNY10605133709252DE501C311B
FieldValueIRS element (for citing)
Receipt Of Int Annts Rnts RyltsfalseReceiptOfIntAnntsRntsRyltsInd
Gift Grnt Or Cap Contri To Oth OrgfalseGiftGrntOrCapContriToOthOrgInd
Gift Grnt Cap Contri From Oth OrgYes (true)GiftGrntCapContriFromOthOrgInd
Loans Or Guarantees To Other OrgYes (true)LoansOrGuaranteesToOtherOrgInd
Loans Or Guarantees From Oth OrgfalseLoansOrGuaranteesFromOthOrgInd
Div Related OrganizationfalseDivRelatedOrganizationInd
Asset Sale To Other OrgfalseAssetSaleToOtherOrgInd
Asset Purchase From Other OrgfalseAssetPurchaseFromOtherOrgInd
Asset ExchangefalseAssetExchangeInd
Rental Of Facilities To Oth OrgfalseRentalOfFacilitiesToOthOrgInd
Rental Of Fclts From Oth OrgfalseRentalOfFcltsFromOthOrgInd
Perform Of Services For Oth OrgfalsePerformOfServicesForOthOrgInd
Perform Of Services By Other OrgfalsePerformOfServicesByOtherOrgInd
Sharing Of FacilitiesYes (true)SharingOfFacilitiesInd
Paid Employees SharingYes (true)PaidEmployeesSharingInd
Reimbursement Paid To Other OrgfalseReimbursementPaidToOtherOrgInd
Reimbursement Paid By Other OrgfalseReimbursementPaidByOtherOrgInd
Transfer To Other OrgfalseTransferToOtherOrgInd
Transfer From Other OrgfalseTransferFromOtherOrgInd

Transactions Related Org TransactionsRelatedOrgGrp (3 entries)

Transaction TypeTransactionTypeTxtInvolvedInvolvedAmtMethod Of Amount DeterminationMethodOfAmountDeterminationTxt
THE LEUKEMIA & LYMPHOMA SOCIETY
D$87,012COST
OF CANADA
THE LLS RESEARCH PROGRAMS INC
C$58,002COST

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferenceSCHEDULE RFormAndLineReferenceDesc
ExplanationTHE LEUKEMIA & LYMPHOMA SOCIETY OF CANADA CARRIES OUT THE SAME PRIMARY ACTIVITIES AS THE LEUKEMIA & LYMPHOMA SOCIETY, INC. IN CANADA. THE LEUKEMIA SOCIETY RESEARCH PROGRAMS, INC. AND THE LEUKEMIA RESEARCH FOUNDATION, INC. SUPPORT THE ACTIVITIES OF THE LEUKEMIA & LYMPHOMA SOCIETY, INC.ExplanationTxt

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.